speakers annual sachs cancer bio partnering forum€¦ · speakers annual sachs cancer bio...

SUPPORTING ORGANISATIONSORGANISERS

PRESENTING COMPANIES

WELCOM

ESPEAKERS

Annual

Sachs Cancer Bio Partnering Forum

Promoting Public & Private SectorCollaboration & Investment in Drug Development

www.sachsforum.com

21st-22nd May 2013Westin Copley Place, Boston

Conference Guide

SA

CH

S

CA

NC

ER

B

IO

P

AR

TN

ER

IN

G

FO

RU

M



WELCOM

ESPEAKERS

Sachs Associates

Cancer Bio Partnering Forum


t back :: next u

Request for PresentationsPlease use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

Sachs Associates are delighted to welcome you to the:

General Information• The registration desk is open from 8.00am on 21st May and 8.00am on 22nd May although

you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

• The one-to-one meetings are being held in the St. George room Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance.

Sachs Associates, building upon it’s many years of expertise in organizing premier

partnering and investor meetings in Europe and the United States, is proud to

welcome you to the Sachs Cancer Bio Partnering Forum being held on 21st – 22nd May, 2013 at The Westin Copley Place, Boston. This forum

is designed to bring together thought leaders from cancer research institutes,

patient advocacy groups, pharma and biotech to facilitate partnering and funding/

investment.

Sachs Associates would like to thank our sponsors and partners who have helped

make this event possible.

Sachs Cancer Bio Partnering ForumPromoting Public & Private SectorCollaboration & Investment in Drug Development 21st-22nd May 2013 • Westin Copley Place, Boston



WELCOM

ESPEAKERS

Sachs Associates



t back :: next u

Events Diary

13th AnnualBiotech in Europe Investor Forum30th September - 1st October 2013 • Hilton Zurich Airpot Hotel

Back for its 13th year, the Biotech in Europe Investor Forum will once again be held in Zurich. Featuring our core sponsors, an audience of over 400 investors, analysts & media, with presenting opportunities for over 60 public and private companies and panel themes including Finance & Investment, Partnering and more, this event is a must for all key players in the Biotech and Pharma industry.

The forum will be an excellent platform for companies to raise their profile by promoting their interests to the larger financial community. Facilitated by its successful one-on-one meeting system and networking receptions, the event will help build strong and meaningful business relationships through face to face communication, and promises to be a great opportunity to meet emerging companies, leading global investors, analysts, advisors and Big Pharma representatives. Panel discussions with participation from industry leaders and experts in their sector, makes the Biotech In Europe Investor Forum an excellent way to gain insight and keep up to date with partnering and investment and current industry trends.

http://www.sachsforum.com/zurich13

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Zoe Harris on [email protected]



WELCOM

ESPEAKERS

Sachs Associates



Speakers

t back :: next u

Alykhan Shamji, Associate Director, Chemical Biology Program, Broad Institute of Harvard and MIT

Alykhan Shamji joined the Broad Institute as the Associate Director of the Chemical Biology Program in 2007. He works closely with Broad investigators interested in applying chemical biology approaches to advance the mission of the institute: accelerating the understanding and treatment of disease. He leads a research group in this area, and oversees the financial and operational administration of the program.

His work focuses on the discovery and characterization of small molecules with potential to impact disease research and medicine. Working with the scientific community, his group aims to understand the relationship between disease genetics, pathophysiology, and the response to small molecules, with the goal of defining and testing strategies for therapeutic intervention. His projects focus on cancer, diabetes, and inflammatory bowel disease.

Before joining the Broad, Shamji was a management consultant at the Boston Consulting Group, focusing on pharmaceuticals, clinical diagnostics, and strategic acquisitions. He received both his A.B. in biochemical sciences and his Ph.D. in biophysics from Harvard University.

Anne Altmeyer, Vice President, Business Development & Licensing, Novartis

Anne Altmeyer is a Vice President in Business Development and Licensing in the Oncology Business Unit at Novartis, USA. Her responsibilities are to in-license or acquire Oncology assets that can further strengthen the Novartis Oncology portfolio. In this role, she identifies, evaluates, and negotiates transactions for oncology opportunities. She also manages several ongoing alliances.

Anne has over 15 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in Research, Development, and Business Development and Licensing. Anne joined the Oncology Project Management group of Novartis in 2004 as a Project Leader. There she led numerous multidisciplinary Project Teams through the generation and implementation of strategies for various compounds in development and on the market. Before joining Novartis, Anne worked as a Project Manager in various Therapeutic Areas at Merck & Co. for about 4 years and as a Visiting Research Scientist for 2 years.

Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral fellowship at New York University School of Medicine, USA, and subsequently became a Research Associate at Cornell University Medical College, New York, USA. In addition to her scientific training, Anne also received a Master in Business Administration and a Master in Public Health from the University of Medicine and Dentistry of New Jersey/Rutgers, USA.

Aaron Reames, Senior Equity Analyst, Columbia Management

Aaron Reames is a senior equity analyst for Columbia Management Investment Advisors, LLC (CMIA). Mr. Reames is responsible for equity research and coverage of the biotechnology and emerging specialty pharmaceutical sectors. He joined the firm in 2010 and has been a member of the investment community since 1998.

Prior to joining Columbia, Mr Reames worked as a senior analyst at Wells Fargo Securities (formerly Wachovia) where he was a Director, Equity Research and Senior Analyst covering the biotechnology sector. He covers a broad range biotechnology companies focused on developments in the areas of oncology, antiretrovirals, cardiology, metabolic disorders and CNS. Reames joined Wells from AG Edwards where he was a Vice-President covering the same space.

Before beginning his career as a sell-side analyst, Mr. Reames was director of the Biotechnology Group for JPS Capital, where he led licensing deals, M&A transactions and partnerships. He was also a performance measurement and investment analyst at Banc One Investment Advisors, the investment arm for Bank One Corporation (now JPMorgan Chase & Co.). In addition, he has served as an adjunct professor of finance at Columbus State University in Columbus, OH.

Mr. Reames brings 11 years of biotechnology and molecular genetics laboratory experience in the fields of entomology, microbiology, molecular genetics and muscle physiology. He research was conducted at the labs of The Ohio State University and Case Western Reserve University, with internships at Lawrence Berkley. Mr. Reames has received accolades for research he conducted in the filed of molecular genetics from former President of the United States George Bush Sr. and the Governor of Ohio. He has also received commendations from the U.S. Navy, Army and Marine Corp for excellence in research and has been recognized by the American Academy for the Advancement of Science, National Academy of Science, National Association of Biology Teachers, American Society for Microbiology and NASA.

Mr. Reames received his B.S. in biology from Ohio State University and his M.B.A from Franklin University in Columbus, Ohio.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Armen Shanafelt, Venture Partner, Lilly Ventures

Dr Shanafelt is a Venture Partner at Lilly Ventures, and has over 22 years of experience in the pharmaceutical, biotechnology and diagnostic businesses. Prior to joining Lilly Ventures, he was CSO responsible for the generation of the biotherapeutic pipeline for Lilly, including the therapeutic areas of oncology, endocrine, neuroscience, and autoimmunity. He currently serves as a director on the boards of HemaQuest Pharmaceuticals, Protagonist Therapeutics, and Sutro Biopharma, and is a Kauffman Fellow (Class 14).

Aya Jokobovits, Venture Partner, Orbimed Israel and CEO, Kite Pharma

Dr. Jakobovits serves as President & Chief Executive Officer of Kite Pharma, Inc. and as a Venture Partner with Orbimed Israel Partners. Kite, her fourth biotech start-up, is developing immunotherapies that restore the patient’s immune system to fight cancer. Prior to joining Kite, Dr. Jakobovits served as Executive Vice President, Head of Research and Development at Agensys, Inc., an affiliate of Astellas Pharmaceuticals, Inc., which acquired Agensys in a deal valued at $537 million in December 2007. Prior to the acquisition, Dr. Jakobovits served as Senior Vice President, Technology and Corporate Development, and Chief Scientific Officer of Agensys, which she joined in 1999 and led its transition from a small gene discovery lab into a fully integrated biotech company. Under her leadership, the company established a large proprietary portfolio of novel cancer targets protected by a strong patent estate, a clinical pipeline of therapeutic human antibodies in multiple cancer indications, and partnerships with Genentech, Merck, Sanofi-aventis and Seattle Genetics.

Before joining Agensys, Dr. Jakobovits served as the Director, Discovery Research and Principal Scientist at Abgenix, Inc, which was spun out of Cell Genesys in 1996, based on XenoMouse® technology developed under her leadership. Abgenix was acquired by Amgen, Inc. for $2.2 billion. Dr. Jakobovits initiated the development of XenoMouse® technology in 1989 at Cell Genesys, Inc., where she was a scientist founder and served as Director of Molecular Immunology. Dr. Jakobovits was a postdoctoral fellow at Genentech, Inc. and at the University of California, San Francisco. She received her Ph.D. in Life Sciences from the Weizmann Institute of Science in Rehovot, Israel. Dr. Jakobovits is an author of over 50 scientific publications and inventor on over 100 patents related to XenoMouse® technology, proteomics technology, novel cancer targets and antibody therapeutics.

Ansbert Gadicke, Managing Director, MPM Capital

Dr Ansbert Gadicke is a Co-Founder and Managing Director of MPM Capital. He led MPM’s effort to build its Advisory and Investment Banking business from 1992 to 1996 and started its Asset Management business in 1996.

Prior to founding MPM, Dr. Gadicke was employed by The Boston Consulting Group. Dr. Gadicke received an M.D. from J.W. Goethe University in Frankfurt. He held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT and the Biochemistry Department at Harvard University. At the German Cancer Research Center, Dr. Gadicke cloned the first cDNAs of HPV16 and 18 in Prof. Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Dr. Gadicke has published in leading scientific publications including Nature and Cell.

He is a member of the Board of Fellows of Harvard Medical School and the MGH Research Advisory Council.

Past Boards: BioMarin Pharmaceuticals, Inc. (NASDAQ:BMRN) • Biovitrum AB (Stockholm:BVT) • Chiasma, Inc. •Coelacanth Corp. • Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) •Kourion Therapeutics AG (acquired by VIAC) •MediGene AG (Frankfurt:MDG) • Omrix (NASDAQ:OMRI) (acquired by JNJ) • National Venture Capital Association • Pharmasset, Inc. (NASDAQ:VRUS) (acquired by GILD) • PharmAthene (PIP) • Solasia Pharma K.K., Tokyo • Transform (acquired by JNJ) • Verastem, Inc. (NASDAQ:VSTM) • ViaCell (NASDAQ:VIAC) (acquired by PKI).



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Dr Bruce Crise, Director of Business Development, Frederick National Laboratories

Dr. Bruce Crise serves as Director, Business Development for Scientific and Technical Operations in the Partnerships Development Office at the Frederick National Laboratory for Cancer Research (FNLCR), SAIC-Frederick since 2008. In this capacity, he leads the business development activities and serves as a scientific and technical liaison in the assessment of R&D partnerships. He plays a key role in enabling the life sciences mission of FNLCR through partnership development, advancing strategic alignment between SAIC-Frederick and NCI on opportunities for collaborations related to cancer and AIDS research. Dr. Crise joined SAIC-Frederick in 2000, and prior to his current role, he held scientific management positions as director of the Gene Expression Laboratory and as the senior scientist in the Retroviral Vaccine Laboratory. Prior to 2000, he conducted research at the U.S. Army Medical Research Institute of Infectious Diseases, developing medical countermeasures to biological weapons. Dr. Crise earned his Ph.D. from Yale University, where he studied molecular aspects of HIV infections, and conducted his post-doctoral fellowship at the Salk Institute. He has extensive R&D experience in the field of molecular virology, vaccine development, cell biology and genetics.

Beth Jacobs, Managing Director, Excellentia Global Partners

Beth Jacobs currently serves as Managing Partner of Excellentia Global Partners, a global life sciences investment bank, founded in 2008. Most recently, Beth was a General Partner at Bio-IB, a lifesciences-focused investment bank in New York.

Beth has served in senior executive roles in her twenty five years of experience in both investment banking and in the corporate sector. Prior to 2003, Beth was Managing Director and Co-Head of Global Capital Markets at ING Barings, shortly after their acquisition of Furman Selz LLC, where she founded and led its international institutional equity group for over 7 years. She started her career at Prudential Securities where she founded the international institutional equity business, and later headed the same product execution group at both Morgan Stanley and Lehman Brothers.

She currently serves on the Board of Directors of EF Foundation, a global educational services company based in Stockholm and Cambridge, Mass, Board of Governors of the New York Academy of Sciences, founding Global Ambassador for Susan G. Komen for the Cure, Board member for both the Harvard Kennedy School of Government Women’s Leadership Board and the Women’s Forum of New York, and as Vice Chairman of the Board for the Budapest Festival Orchestra.

Beth received an MBA in international finance from American University in Washington, DC in conjunction with the School of Foreign Service, and a BA, cum laude, from Boston College. She also studied at Centre d’Etudes Internationale in Geneva, Switzerland.

Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance

Darryl Mitteldorf, LCSW, is an oncology social worker. Mr. Mitteldorf is the founder and Executive Director of America’s largest men’s cancer survivor support and advocacy nonprofit organization, Malecare. In 2011, working through Malecare in collaboration with several international NGO’s, Mr. Mitteldorf founded the Global Prostate Cancer Alliance. Mr. Mitteldorf is widely published, has spoken at numerous professional conferences and sits on the Board of Directors and Board of Advisors of several cancer focused nonprofit organizations, including the National LGBT Cancer Project-Out With Cancer, The New York State Prostate Cancer Coalition and the Education Network to Advance Clinical Trials. Mr. Mitteldorf holds two Masters degrees from New York University and a BA from Swarthmore College.

Dan Snyder, President and COO, MolecularMD

Dan Snyder has more than 15 years of experience in the life science research and diagnostic fields supporting the market development of high value products and services to both pharmaceutical and academia clients. Mr. Snyder has worked extensively in supporting new product introductions and rapid market adoption for novel proteomic and genomic technologies. His commitment to customer satisfaction and close interaction with MolecularMD’s assay development laboratory helps to ensure MolecularMD meets or surpasses all client expectations.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Dennis J. Purcell, Senior Managing Director, Aisling Capital

Dennis J. Purcell has served as the Senior Managing Director of Aisling Capital since February 2000 and is responsible for the management of the Partnership. The fund has approximately $1.7 Billion of assets under management.

Prior to joining Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at Hambrecht & Quist, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries.

During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP and honored as one of the top 50 Irish- American businessmen and cited as the top 100 contributors to the biotechnology industry. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell currently serves as a director of Paratek Pharmaceuticals, Inc., and Xanodyne Pharmaceuticals, Inc. Previously he served as a director of Aton Pharmaceuticals, Inc., Bridge Pharmaceuticals, Inc., Cengent Therapeutics, Inc., Dynova Laboratories, Inc., and Valentis, Inc.

He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association and the Irvington Institute. He also serves on the Board of L.E.K. consulting.

Mr. Purcell received his M.B.A. from Harvard University, and his B.S. in Accounting from the University of Delaware.

Doug Cole, General Partner, Flagship Ventures.

Doug Cole joined Flagship in 2001 where he focuses on Life Science investments. Dr. Cole holds an AB magna cum laude with High Distinction in English from Dartmouth College, and an MD from the University of Pennsylvania School of Medicine. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, MD and in neurology at the Massachusetts General Hospital in Boston, MA. In 1992, Dr. Cole was appointed Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at the Massachusetts General Hospital. He established a research program investigating the mechanistic basis of neuronal signaling events and plasticity in neuro-psychiatric disorders with the support of the NIH and several non-profit research foundations. In 1996, Dr. Cole joined Cytotherapeutics, in Providence, RI. As Medical Director, he oversaw various research and clinical activities related to the company’s cell-based therapeutic technologies. In 1997, he was appointed Program Executive at Vertex Pharmaceuticals, Inc. where he led a multidisciplinary program that conducted preclinical development through Phase II studies in tissue protection and repair, oversaw an international research collaboration, and was responsible for identifying strategic market and technology opportunities in multiple arenas. At Flagship, Dr. Cole has led investments in CombinatoRx, Tetraphase Pharmaceuticals, Alvine Pharmaceuticals, Concert Pharmaceuticals, Quanterix Corporation, Receptos, Agios Pharmaceuticals, Seventh Sense Biosystems, and Avedro. He is a co-founder of Flagship portfolio companies Ensemble Therapeutics, Permeon Biologics, ModeRNA Therapeutics, and Syros Pharmaceuticals. He currently serves on the Board of Directors of Tetraphase Pharmaceuticals, Concert Pharmaceuticals, Quanterix Corporation, Receptos, Agios, Selecta Biosciences, Avedro, and Syros.

David Malek VP, Business Development, BioLineRx Ltd

David Malek was appointed as Vice President of Business Development in October 2011. Prior to joining BioLineRx, since 2006, Mr. Malek served at Sanofi in a number of management positions in the US and France, including Marketing, Finance and Business Development. Most recently Mr. Malek served as Director of Oncology - New Products and Business Development.

Mr. Malek has an MBA from the Tuck Business School at Dartmouth College and also holds a BA in Statistics and Political Science from the University of Haifa.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Douglas M. Fambrough, CEO, Dicerna Pharmaceuticals

Doug is CEO of Dicerna Pharmaceuticals, a second generation RNA Interference company which he co-founded in 2007, based on breakthrough “Dicer Substrate” technology that optimizes activity and facilitates drug delivery. Prior to taking the CEO role at Dicerna, Doug was a General Partner with the Boston-based life science venture capital firm Oxford Bioscience Partners. During his 10+ years at Oxford, Doug specialized in financing innovative life science technology companies, such as first generation RNA Interference pioneer Sirna Therapeutics, acquired by Merck for $1.1 billion; Solexa, developer of the dominant ultra-high-throughput DNA sequencing platform, acquired by Illumina for $600 million; and Cambrios Technologies, which invented and now markets biologically-inspired electronic materials for touch screens and flat panel displays. Before joining Oxford, Doug was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute). He graduated from Cornell University and obtained his Ph.D. in Genetics at the University of California, Berkeley.

Professor Edward J. Benz, Richard and Susan Smith Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Harvard Medical School, President, Dana-Farber Cancer Institute

Professor Edward J. Benz, Jr is President and CEO of the Dana-Farber Cancer Institute and the Richard and Susan Smith Professor of Medicine, professor of pediatrics, and professor of pathology at Harvard Medical School. Dr. Benz was elected to The Rockefeller University Board of Trustees in 2004.An internationally recognized hematologist, he is an expert in inherited anemias and diseases of the red cell. His laboratory studies, which are funded by the National Institutes of Health, focus on the molecular regulation and functions of membrane cytoskeletal proteins that were originally discovered in the red blood cell.

Dr. Benz is also CEO of Dana-Farber/Partners CancerCare, Principal Investigator and Director of the Dana-Farber/Harvard Cancer Center, Director of Dana-Farber/Brigham and Women’s Cancer Center, and a member of the Governing Board of Dana-Farber/Children’s Hospital Cancer Center.

Dr. Benz graduated from Harvard Medical School and received his training at Brigham and Women’s Hospital. He later served as Chair of the Departments of Medicine at the University of Pittsburgh and then at Johns Hopkins, where he held the prestigious Sir William Osler Professorship of Medicine. He currently serves as Past President of the Friends of the National Institute of Nursing Reseaerch, and has been elected President of the American Association of Cancer Institutes.

Dr. Benz’s many honors include membership in the Institute of Medicine of the National Academy of Sciences and the American Association of Arts and Sciences. He has served on numerous NIH committees and currently chairs the NIH Advisory Board for Clinical Research. He is a past president of both the American Society of Hematology and the American Society of Clinical Investigation. Dr. Benz is married to Dr. Margaret Vettese, a nurse scientist and educator. They have four children.

Doug Plessinger, VP of Clinical and Medical Affairs, Argos Therapeutics

Doug Plessinger joined Argos Therapeutics in 2011 after serving as a clinical consultant for the company for the previous 4 years. Prior to joining Argos, Mr. Plessinger was an original founder and served as the Executive Vice President and Managing Director for Axcelo MSL Solutions, a Medical Affairs and MSL consulting company. Prior to this, he served as Senior Vice President of Client Services at The Navicor Group and in other roles with Navicor and affiliated inVentiv Health companies from 2003 to 2007. Mr. Plessinger also served as a lead Medical Science Liaison (MSL) for Millennium Pharmaceuticals and held various roles of increasing responsibility for Bristol-Myers Squibb in Oncology Medical Affairs and Oncology Global Marketing from 1997 - 2003. Overall, he has more than 20 years of clinical pharmacy, pharmaceutical, and client-services related experience, including the development and launch of multiple oncology products across various solid and hematologic malignancies. Mr. Plessinger holds a B.S. degree in Pharmacy and graduated summa cum laude from Northeastern University.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Esteban Pombo Villar, Chief Operations Officer, Oxford BioTherapeutics AG

Esteban Pombo Villar is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry.

Florian Schödel, CEO, Phillimmune LLC

Florian Schödel is the founder of Philimmune LLC, a consulting firm which provides strategic advice in the development of biologics, vaccines and pharmaceuticals. Florian has > 20 years of successful experience in leading teams in the development of vaccines and biologics in the pharmaceutical and biotech industry and in academia.

His passion is preventative medicine and the use of modern science and technology for the improvement of public health – especially in the development of preventative and therapeutic vaccines and biologics.

Florian has a track record in running scientific and operational organizations, in business and strategic planning, for forming international strategic partnerships and alliances, in target identification and in all steps of clinical and pre-clinical development.

He has directed the design and execution of clinical studies for licensure and routinely interacts with international and national regulatory agencies.

Florian has led the clinical teams responsible for several successful vaccine filings.

A physician and microbiologist by training, Florian was a VP in Vaccines Clinical Research of Merck Research Laboratories before he founded Philimmune.

Florian graduated in medicine at the Technical University, Munich, and earned doctorates in Transplantation Immunology and Medical Microbiology (Dr. med. Dr. med. habil.) from the University of Munich (LMU). He holds adjunct faculty appointments at the LMU and at the Biodesign Center of the ASU. Florian’s research at the Max-Planck Institute for Biochemistry, at Scripps, WRAIR and INSERM focused on hepatitis B and on novel recombinant vaccines against diseases such as hepB, malaria and typhoid.

Florian joined Merck Research Laboratories in 1996 as Director Clinical Vaccine Research leading EU vaccine clinical trials and the clinical development of rotavirus vaccines and varicella, measles, mumps, rubella combination and shingles vaccines. As the clinical liaison to an EU joint venture (SP-MSD) he participated in the development of pediatric combination vaccines.

Eric Risser, Vice President, Business Development, MacroGenics, Inc.

Eric Risser has over 15 years of strategy and transaction experience across both small biotechnology and large pharmaceutical companies. During his career, he has led multiple major transactions in the pharmaceuticals area, including company acquisitions, divestments, equity financings, product licenses and research collaborations. He currently leads the business development activities at MacroGenics, and was responsible for the execution of MacroGenics’ existing partnerships with Gilead, Servier, Pfizer, Boehringer Ingelheim, and Green Cross. Prior to joining MacroGenics, he served as Executive Director, Business Development at Johnson & Johnson Pharmaceuticals, which he joined in 2003. Before Johnson & Johnson, Mr. Risser started and built a successful consulting practice that provided counsel to emerging life science companies in the United States and Europe. He has also worked as a venture capitalist with BankAmerica Ventures and as an investment banker with Lehman Brothers, where he began his career in their New York and London offices. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.

.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Frank Jones, Presdient, CEO, CSO, Etubics Corporation

Dr Jones is a founder of Etubics Corporation and is the Company’s Chairman, Chief Executive Officer and Chief Scientific Officer. Dr. Jones has raised over $16 million for Etubics through venture capital and non-dilutive National Institutes of Health grants and contracts. He has brought the Company through the pre-clinical phase and the FDA evaluation and approval process to initiate CEA clinical trials at Duke University Medical Center.

From 1981 to 1996, Dr. Jones was a Founder and served as Chairman and Chief Executive Officer of IMRÉ Corporation, a publicly traded company. He raised over $100 million via private placements, corporate alliances, and three public offerings at IMRÉ. He also directed the Company through the start-up phase, technology development, pre-clinical studies, GMP production of its own product, preparation of patent applications for product and treatment protection, clinical trials, preparation and submission of investigational device exemptions (IDE’s), submission of pre-marketing approval application data (PMA), and submission of post market approval data and documents to the FDA. Dr. Jones did the basic research for the Company’s products, wrote the treatment protocols for the human clinical trials and recruited clinical sites to test products. His area of medical and product focus is targeted at cancers and infectious diseases- with a goal of development of an armamentarium necessary to modulate and control the human immune system. Dr. Jones built strong, internationally recognized management and scientific teams to lead the Company into the production and marketing phases of corporate development; negotiated strategic alliances for clinical research and marketing of corporate products around the world and within the United States. He was the standard bearer for IMRÉ Corporation in the investment banking and finance arena as well as the scientific world.

From 1983 to 1986, Dr. Jones was Chairman of the Immune Response Program of the Pacific Northwest Research Foundation in Seattle. Dr. Jones was a Researcher in the Department of Complement and Effector Biology at Memorial Sloan Kettering Cancer Center (“MSKCC”) in New York City from 1980 to 1981 and was a Associate in the Laboratory of Veterinary Oncology at MSKCC from 1981 to 1983.

Dr. Jones holds a PhD degree from the University of Washington in Biological Structure/Cellular Immunology. He has 11 issued patents to his name, has published over 45 scientific papers, and given many business and scientific presentations on an international basis.

Guillaume Vignon, Director Business Development Oncology, Global Business Development and Licensing, Merck Serono S.A.

Guillaume Vignon is Director of Business Development Oncology with Merck Serono, responsible for designing deal structures and negotiating the terms of complex strategic transactions in the field of Oncology. Prior to this position, Guillaume was Director of Strategic Transactions, focusing on pre-clinical stage assets, enabling technology, antibody platforms, and companion diagnostics. During his career at Merck Serono, Guillaume closed successfully several key partnerships for Merck Serono in the field of Oncology, Companion Diagnostic, and Antibody Discovery.

Before his positions as global transactor, Guillaume served as inhouse consultant for Merck KGaA, Damstadt, Germany, leading several assignments in the field of management strategy, implementation, commercial operations BU Oncology, and business planning BU Oncology.

Guillaume holds an MBA from Hult International Business School, Cambridge, USA, and a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Pasteur Institute, Paris, France.College, UK.

Hamza Suria, President & CEO, AnaptysBio

Hamza Suria joined AnaptysBio in December 2008 and has been CEO since 2011. Prior to AnaptysBio, Mr. Suria was at Maxygen, where he was responsible for partnering and alliance management of next-generation protein therapeutics with Roche, Sanofi-Aventis, Bayer, Astellas and others. Before Maxygen, Mr. Suria was responsible for business development at Diabetogen Biosciences and Viron Therapeutics. Suria holds a B.Sc. in biochemistry from Kalamazoo College, an M.S. in immunology from the University of Western Ontario and an Executive MBA from the Richard Ivey School of Business.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Henry McCusker, Director, Scimitar Equity Research

Founder and Director of Research, Henry McCusker enters his twelfth (12) year at Scimitar Equity, LLC. Past experience in sell-side analysis, buy-side management and due diligence provide keen insight and define a unique ability as a research provider.

He was VP - Strategic Planning and Communication at Curis, Inc. (2001-2002) where he was responsible for the first restructuring and the second realignment. Henry worked with Hambrecht and Quist Capital Management (HQCM) focusing on healthcare investments (NYSE:HQH/HQL) from 1985 through 2001. He also founded LifeScience Economics, a healthcare research and analytics firm with offices in Boston, MA and Palo Alto, CA.

Past experiences include manager/director at Thermo Electron, and Stone and Webster following five years at the Federal Bureau of Investigation. A former military officer, Henry has been an adjunct professor at Boston University and Golden Gate University where he taught courses in venture capital, corporate finance and strategic development in the universities’ graduate business schools.

Harry Glorikian, Managing Partner, Scientia Partners

Harry Glorikian heads Scientia Advisors with 20 years of experience in the health care and life science industries. He is known worldwide as a leader in helping companies streamline their operations and accelerate their growth.

Having held senior management positions at Applied Bio Systems, Signet Laboratories, in Massachusetts, and at X-Cell Laboratories, Inc., in California, Harry has deep commercial background in diagnostics, molecular biology, proteomics, cellular biology and biodefense. His unique understanding of technologies, operations and strategy from both customer and industry player perspectives has shaped Scientia’s sophisticated framework and proprietary analytic tools.

A sought-after speaker, Harry has addressed the National Institutes of Health, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles for industry publications, appeared on CBS Evening News and been quoted by Dow Jones, the Boston Globe, BioWorld Today, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine and many other media outlets.

Harry holds an MBA from Boston University and a BA in Biology from San Francisco State University. He serves on many advisory boards and is an avid inventor who has several patents and patents pending in the US and abroad.

Jeffrey Cohen, Director, Healthcare Research, Ladenburg Thalmann & Co.

Jeffrey Cohen has over 20 years of professional experience involved in the worldwide financial markets including such companies as Cantor Fitzgerald, the American Stock Exchange (NYSE Euronext), Sanwa Bank and Ladenburg Thalmann. For the past 13 years, Mr. Cohen has been actively involved in direct research, analysis and marketing pertaining to the large and growing $2.7 trillion US healthcare sector, including detailed fundamental and financial analysis specific to the development, marketing, delivery and commercialization of medical technologies, therapeutics, and various other healthcare solutions. During the past seven (7) years, Mr. Cohen has developed, published and presented detailed fundamental analytical reports and financial models for more than 34 publicly traded and privately held medical technology, healthcare service and biotechnology companies with over $14 billion in aggregate market capitalization. Mr. Cohen is an engineer by early training and education

(BSE University of Pennsylvania), including several years of work experience planning, designing and implementation of complex fixed-rail automated transportation systems and also holds an MBA and various FINRA licenses.

Ingmar Hoerr, CEO, CureVac

Ingmar Hoerr, PhD, MBA, Chief Executive Officer founded CureVac with colleagues Florian von der Muelbe and Steve Pascolo during his PhD work at the University of Tuebingen. His scientific background includes working with Professor Guenther Jung and Professor Hans-Georg Rammensee, renowned scientists in organic chemistry and immunology, respectively.

During his one year stay in India he also carried out field studies on leprosy and HIV in collaboration with the World Health Organisation (WHO) at Madurai Kamaraj University. Ingmar Hoerr received his PhD in biology from Tuebingen University, and an MBA from Danube University in Krems, Austria.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Jeremy P. Goldberg, Advisor, Torreya Partners

Jeremy P. Goldberg is a skilled business development executive with over 25 years of experience, mainly focused on investing and business development in the pharmaceutical and healthcare industries. In addition to his work as Advisor at Torreya, he is an advisor to several funds focused on private equity and life sciences investments in the venture and royalty areas. He was a founding partner of ProQuest Investments in 1998, the first cancer-focused venture capital fund, where he and his partners raised over $250 million in Funds I and II to acquire positions in biotechnology, specialty pharmaceutical and medical device companies. Jeremy joined Endo Pharmaceuticals in 2003 as Managing Director, Corporate Development and was responsible for its overall corporate development activities, including structuring, negotiating and closing transactions. Jeremy’s transaction experience includes over 12 product licenses and multi-product license or acquisitions with U.S. and European companies announced while at Endo Pharmaceuticals. Prior operating experience includes roles as founding CEO or founder of three biotechnology companies that were acquired or taken public, including Versicor (Vicuron), a Sepracor spin-out later acquired by Pfizer, and operating roles at SmithKline and Becton Dickinson. He serves on the Dana Farber Cancer Institute Lank Center Visiting Committee and an NIH-Oxford affiliated board. Jeremy received his A.B. from Harvard College and M.B.A from Harvard Business School.

John Gustofson, Director, Business Development, AstraZeneca

John Gustofson is a Director of Strategic Partnering and Business Development at AstraZeneca. In his current position, John is responsible for identifying, evaluating and negotiating early preclinical to late stage clinical opportunities with a focus on Oncology. John has 19+ years professional experience with early stage biotechnology and pharmaceutical industries. In addition, John spent approximately 4 years in strategy consulting to the life sciences industry. Prior to joining AstraZeneca John held business and market development positions at Altus Pharmaceuticals and Therion Biologics.

John M. Lambert, EVP and Chief Scientific Officer, ImmunoGen, Inc.

Dr. John M. Lambert is Executive Vice President and Chief Scientific Officer at ImmunoGen, Inc., a biotechnology company with headquarters inWaltham, Massachusetts.

Dr Lambert received a BA in Natural Sciences in 1972 from the University of Cambridge, England, and received a Ph.D. degree in Biochemistry in 1976, also from the University of Cambridge, for his research on the structure of multimeric glycolytic enzymes under the supervision of Professor Richard N. Perham.

He did his postdoctoral training working in the laboratory of Dr Robert R. Traut in the Department of Biological Chemistry, School of Medicine, at the University of California at Davis, where he worked on the structure of ribosomes (1976 – 1980), and with Dr John R. Coggins in the Department of Biochemistry at the University of Glasgow in Scotland (1980 – 1982), where he worked on the arom multienzyme complex.

In 1982, Dr. Lambert joined the Sidney Farber Cancer Institute (later renamed Dana-Farber Cancer Institute), Harvard Medical School, as an Assistant Professor of Pathology, to work with Dr Walter A Blättler on the research program that was funded by ImmunoGen, Inc., to develop anti-cancer therapeutics based on the concept of utilizing monoclonal antibodies to deliver cytotoxic payloads (ADCs) to kill the targeted cancer cells.

In 1987, the ADC research program moved to independent laboratories established by ImmunoGen in Cambridge, Massachusetts, where Dr Lambert was appointed Senior Scientist. In 1990, Dr Lambert became Director of Biochemistry, and in 1992 was appointed Senior Director of Research. He joined the Senior Management team of the Company as a Vice President in 1994, and served in a variety of roles until becoming EVP and Chief Scientific Officer in 2009.

Dr Lambert is the author/coauthor of over 100 scientific articles.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Jonathan Burgin, CEO, BioCancell Ltd

Jonathan Burgin has served as Chief Executive Officer of BioCancell since June 2012, and was previously Chief Financial Officer of the Company from June 2011. Mr. Burgin has been Chief Financial Officer of Radcom, Ltd. (NASDAQ: RDCM), a service assurance provider, since 2006, and was CFO of XTL Biopharmaceuticals (TASE: XTL, Pink Sheets: XTLBY), a drug development company, from 1999 to 2006, where he took an active part in the process of listing its shares on the NASDAQ, London Stock Exchange, and TASE and in raising $113 million in four financing rounds. Between 1997 and 1999, he was CFO of YLR Capital Markets, a publicly-traded Israeli investment bank, and rose to become a Senior Manager at Kesselman & Kesselman, the Israeli member of PricewaterhouseCoopers International, Ltd., between 1984 and 1997. Mr. Burgin earned an M.B.A. and a B.A. in Accounting and Economics from Tel-Aviv University and is certified in Israel as a CPA.

Jonathan Pachter, VP, Head of Research, Verastem, Inc.

Dr. Pachter brings over 20 years of experience in leading discovery of small molecule and monoclonal antibody therapeutics for treatment of cancer. He was previously Head of Cancer Biology at OSI Pharmaceuticals where his team was responsible for development of models of tumor cell EMT (epithelial-mesenchymal transition) and discovery of drugs disrupting this process. At OSI he advanced five small molecules into development for treatment of cancer, including OSI-906 – a selective IGF-1R/ insulin receptor kinase inhibitor currently in phase III clinical trials and OSI-027 – a selective mTOR kinase inhibitor. Prior to OSI, Dr. Pachter held positions of increasing responsibility at Schering-Plough where he progressed three agents into development including the monoclonal antibody robatumumab which advanced to phase II clinical evaluation in cancer patients. Dr. Pachter also made key contributions to the regulatory approval of temozolomide for treatment of glioblastoma. He is an author of over 40 peer-reviewed publications and inventor on numerous patents. Dr. Pachter did his postdoctoral work in Pharmacology at Yale University School of Medicine and he holds a Ph.D. from Baylor College of Medicine.

Kevin Krenitsky, Chief Commercial Officer & SVP International Strategy, Foundation Medicine

Dr Krenitsky joined Foundation Medicine as the Chief Operating Officer in June 2011, bringing 15 years of experience in building and managing global diagnostic and biotechnology operations to the company. He joins Foundation Medicine from Enzo Clinical Labs where he served as president. In this role, he instituted a comprehensive operational plan that resulted in re-accreditation by the College of American Pathologists and led the introduction of numerous U.S. FDA-approved esoteric tests as well as several new laboratory developed test rollouts, all of which led to significant revenue growth during his tenure.

Prior to Enzo Clinical Labs, he was chief executive officer at BioServe Biotechnologies, a global biotechnology company specializing in processing genetic diagnostic tests, and before that, he served as chief executive officer at Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. Before joining Parkway Clinical Laboratories, Dr. Krenitsky held multiple senior level positions within Genomics Collaborative, Inc. (a SeraCare Life Sciences Company), a full-scale clinical and genomics research company.

Dr. Krenitsky received a BS in business management from the University of Scranton and an MD from Jefferson Medical College.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Laurent Choppe, Managing Partner, Life Sciences, Cukieman & Co.

Laurent Choppe is leading CLS since 2008 and brings an extensive international life science experience in managing multifunctional teams and setting up new businesses in pharmaceuticals, biotechnology, nutraceuticals, animal health and direct-to-consumer markets. After a veterinary practice and a new venture management experience, he spent 10 years in Schering-Plough in various marketing and general management positions in France, Israel and Canada. He then served as international General Manager of BELLUS Health (ex-Neurochem NASDAQ & TSE), a Canadian biopharmaceutical company mainly involved in orphan drugs and Alzheimer’s disease.

Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d’Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD in Fontainebleau (France). He is married, father of 3 and lives in Lausanne (Switzerland).

Leigh Zawel, Executive Director & Oncology Site Lead, Merck Research Laboratories

Dr. Leigh Zawel joined Merck in 2010, and is the Oncology Site Lead at Merck Research Laboratories (MRL) Boston. In this role, he is responsible for the drug discovery efforts within the department which are focused on the identification of development candidates for programs in the oncology franchise.

Dr. Zawel comes to Merck from Sanofi-Aventis where he was the Director of Cancer Biology. Prior to that he spent 11 years at Novartis Institutes for Biomedical Research/Oncology, where he was the Group Leader for identifying and validating oncology drug targets.

Dr. Zawel has a Ph.D. in Biochemistry, was a Postdoctoral Fellow in the laboratories of Drs. Bert Vogelstein and Ken Kinzler at Johns Hopkins University, his M.S. in Bacteriology from the University of Wisconsin, and his B.S. in Biology from Rutgers University.

Dr. Zawel has published over 25 scientific publications, and is an author on 45 patents covering chemical matter, drug combinations, biomarker utility and gene function in areas of apoptosis, inflammation and TGFB signaling.

Lorenza Castellón, Health & Biotech Equity Analyst, Equity Development Ltd

Lorenza is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations. Equity Development brings together investors and companies by means of writing and distributing detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of experience. Please visit www.equitydevelopment.co.uk for more details and examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector having worked for leading international investment organisations.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Louise Perkins, Chief Science Officer, Melanoma Research Alliance

Dr Perkins was most recently the Chief Scientific Officer at the Multiple Myeloma Research Foundation (MMRF) where she was responsible for the development and execution of the MMRF’s scientific strategy to accelerate development of the next treatments for patients with myeloma, leading to a cure. Her interests center on translational research including target identification, drug discovery and advancement of novel therapeutic approaches. She served as CSO at the MMRF for five years following a research career of 16 years at two major pharmaceutical companies.

While at the MMRF, Dr. Perkins led the continued expansion of its venture philanthropy investments including its Biotech Investment Award and Clinical Fund programs. In addition, she was responsible for the expansion of the MMRF’s Genomics Initiative which sequenced the first myeloma tumor genome in 2009 and has comprehensively analyzed 250 myeloma patient samples with an array of genomic technologies including next-gen sequencing. More recently, Dr. Perkins led the development of the genomics and data sharing strategy underpinning the MMRF’s 1,000 patient longitudinal study, CoMMpasssm, which aims to develop new targets and biomarkers through deep clinical and molecular data capture and analysis.

Prior to joining the MMRF, Dr. Perkins was Director of Cancer Research at Bayer Pharmaceuticals in West Haven, CT, where she contributed to advancing novel targeted therapies toward clinical study, including Nexavar® and other innovative signal transduction inhibitors. While at Bayer, she also served as the Director of Research Licensing and was responsible for oncology licensing activities in support of cancer research programs. Prior to joining Bayer, she led a cancer research group at the Schering-Plough Research Institute in Kenilworth, NJ. In this role, she participated in several early-stage research programs including novel target-finding research using human genomics data.

Dr. Perkins graduated from the University of Michigan with a PhD and MS in Biological Chemistry and conducted postdoctoral studies at Princeton University in the Department of Molecular Biology. She earned her BS in Zoology from the University of North Carolina at Chapel Hill.

Louis DeGennaro, Executive Vice President, Chief Mission Officer, Leukemia and Lymphoma Society

As Chief Mission Officer, Dr DeGennaro’s current responsibilities include oversight of all LLS mission functions including Public Policy, Patient Services and Research with the goal of effectively deploying resources in pursuit of the LLS mission to cure leukemia, lymphoma and myeloma and improve the quality of life for patients and their families. The Society’s mission budget exceeds $150 million annually.

Dr. DeGennaro has more than 25 years of research, drug development and executive management experience in academic and private sector settings. He received his Ph.D. in biochemistry from the University of California at San Francisco and did his post-doctoral research at the Yale University School of Medicine. His previous academic appointments include research group leader, Max Planck Institute in Munich, Germany, where his laboratory was among the first to clone genes expressed exclusively in the nervous system; and associate professor of neurology and cell biology, University of Massachusetts Medical School. Dr. DeGennaro’s private sector positions include: senior director of molecular genetics at Wyeth Pharmaceuticals, Princeton, NJ, where his department contributed to the development of pantoprazole (Protonix®) to treat acid reflux disease, Effexor (Venlafaxine®) for anxiety and depression and Mylotarg® for leukemia; executive vice president for research and development, SynX Pharma, Inc. in Toronto, Canada, where he was responsible for the development of a point-of-care diagnostic test for congestive heart failure; and research manager at Streck, Inc., Omaha, NE where he helped develop a FDA-cleared diagnostic test for AIDS/HIV.

Dr. DeGennaro has been appointed by Kathleen Sebelius, U.S. Secretary of Health and Human Services, to serve as a member of the newly created National Center for Advancing Translational Sciences Advisory Council, and the Cures Acceleration Network Review Board at the National Institutes of Health (NIH) and he serves on the Board of BioTheryX, Inc., an early-stage biotechnology company.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Lynda Chin, Professor, Chair, Dept of Genomic Medicine, Scientific Director, Institute for Applied Cancer Science, M.G. & Lillie A. Johnson Chair for Cancer Treatment and Research, UT MD Anderson Cancer Center

Lynda Chin, M.D. trained as a physician at Albert Einstein College of Medicine in 1993, and is a board-certified dermatologist. She conducted her clinical and scientific training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine where she was appointed Chief Resident of Dermatology. Previous to joining the University of Texas MD Anderson Cancer Center in 2011, she was a member of the Dana-Farber Cancer Institute and Harvard Medical School communities. Chin was one of the founding faculty members and the Scientific Director of the Belfer Institute for Applied Cancer Science.

Chin is the founding chair of the Department of Genomic Medicine at MD Anderson. She also serves as the scientific director of the Institute for Applied Cancer Science, which merges the best attributes of academia and industry to enable science-driven drug discovery. Chin is a leader in translational genomic medicine and her research program spans the fields of transcription, telomere biology, mouse models of human cancer, cancer genomics, and personalized cancer medicine. She is also at the forefront of comparative oncogenomics of mouse and human cancers and its integration with functional genomics to identify novel cancer genes and therapeutic targets.

Chin is also actively involved in The Cancer Genome Atlas, where she holds multiple leadership roles. She is also a member of the Scientific Steering Committee of the International Cancer Genome Consortium. Chin was elected a member of the Institute of Medicine in 2012. She co-founded AVEO Pharmaceuticals in 2002, which emphasizes cancer biology and genetics to identify new cancer targets with tumor maintenance roles. More recently, Chin also founded Metamark Genetics, a diagnostic company that develops function-based prognostic determinants to guide the customized management of early-stage cancer patients with melanoma or prostate cancer. Chin has three young children, ages 11, 10 and 8.

Mara Goldstein, Senior Analyst, Cantor Fitzgerald

Mara Goldstein is a managing director and senior analyst covering the biotechnology sector with Cantor Fitzgerald. Ms.Goldstein’s career in equity research spans a broad continuum of life sciences subsectors, including biotechnology, major pharmaceuticals, drug delivery and specialty pharmaceuticals. Prior to joining Cantor Fitzgerald, Ms. Goldstein was most recently with Thomson Reuters, where she served as director of research Reuters Insight, an independent research services business. Ms. Goldstein was initially responsible for the firm’s healthcare research practice, and later assumed responsibility for all research activities and sectors. Prior to that, Ms. Goldstein was an executive director and senior pharmaceutical analyst at CIBC World Markets, and she also worked at Alex Brown & Sons (now Deutsche Bank) and CS First Boston (now CSFB). Ms. Goldstein has been quoted in publications such as The Wall Street Journal, New York Times and Newsweek, and has appeared on financial television news programs such as CNBC, Bloomberg TV and ABC World News. She holds a bachelor’s degree in economics from Purdue University.

Margaret Anderson, Executive Director, FasterCures

Margaret Anderson is the executive director of FasterCures/The Center for Accelerating Medical Solutions, a Milken Institute center that works to speed up the timeline for new medicines to go from discovery to patients. She is a founding board member and past-president of the Alliance for a Stronger FDA, co-chairs the eHealth Initiative’s Council on Data and Research, and is a member of the National Center for Advancing Translational Sciences Advisory Council, the Cures Acceleration Network Review Board, the National Health Council Board of Directors, United for Medical Research Steering Committee, and the Institute of Medicine’s Forum on Drug Discovery, Development and Translation. Previously, Anderson was the deputy director and a team leader in the Center on AIDS & Community Health at the Academy for Educational Development, where she led public health projects; program director at the Society for Women’s Health Research; health science analyst at the American Public Health Association, where she managed a programmatic portfolio on HIV/AIDS and other sexually transmitted diseases, infectious diseases, women’s health, and public health infrastructure issues; and analyst and project director at the Congressional Office of Technology Assessment in the Biological Applications Program, where she studied societal and business implications of genetic testing. Anderson holds a bachelor’s degree from the University of Maryland and a master’s degree in science, technology, and public policy from George Washington University.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Matthew Callahan, President and CEO, Churchill Pharmaceuticals

Matthew Callahan is the founding CEO of Churchill Pharmaceuticals and is leading the commercialization of the Company’s oral oncology drugs. Mr Callahan developed the concept for Churchill and has positioned the company to rapidly progress its four pipeline products through clinical trials to approval.

Churchill is focused on applying technology to address the significant variability, poor bioavailability and serious side effects of many marketed oral oncology drugs. In some cases, the maximum amount of drug (Cmax) absorbed by patients can vary by 17x and the exposure (AUC) can vary by 10x, depending on the effect of food and patient physiology. Because this sometimes means that patients can absorb little or no drug after taking the dose, the efficacy of these drugs is often retarded. Alternatively, due to the variability of these drugs, patients can receive high or toxic doses which can be related to side effects and can result in treatment interruption.

Churchill is a licensee of the SoluMatrix™ technology platform from iCeutica Inc. This proprietary platform allows for drug particles to be reduced in size down to the sub-micron range, thereby significantly increasing their dissolution performance and improving their bioavailability. SoluMatrix™ has been successfully utilized in a number of products in the pain and inflammation area which have completed Phase 3 trials and the first NDA incorporating the technology has been filed.

Churchill has selected four marketed oral oncology drugs for reformulation using the SoluMatrix™ technology and the first of these is planned to enter clinical development in Q4 2013. The pathway for development of these improved versions of the innovator drugs is relatively efficient, as Churchill intends to rely on a portion of the data for each drug which is already the subject of FDA approval.

Mr Callahan was also the founding CEO of iCeutica Inc and has more than 18 years legal, commercial and IP experience. He remains a partner of an Australian venture capital fund and is also currently a director of cell therapies company Orthocell and carbohydrate drug company Glycan Biosciences. He resides in Philadelphia with his wife and three children.

Matthias Jaffe, CFO, Constellation Pharmaceuticals

Matthias Jaffe joined Constellation in April 2012 bringing over 12 years of experience in corporate finance and strategic management to his role. Previously, he held senior finance and business development positions in a number of private, venture-backed companies in the life science and cleantech space, including Zafgen, Seventh Sense Biosystems, Pervasis Therapeutics and Alantos Pharmaceuticals, which was acquired by Amgen in 2007. Prior to Alantos, Mr. Jaffe was a principal at Earlybird Venture Capital (Munich, Germany), where he supported new investments activities and existing portfolio companies. He also worked at the Boston Consulting Group, where he was a member of the pharmaceutical practice group, assisting Fortune 500 companies with strategic management issues. Mr. Jaffe holds a M.S. in molecular biology from the Massachusetts Institute of Technology, an MBA from INSEAD (Fontainebleau, France).

Michael G. King, Jr, Managing Director and Senior Biotechnology Analyst, JMP Securities LLC

Mike King is a Managing Director and senior research analyst covering the biotechnology industry.

Prior to joining JMP, Mike was a Managing Director at Dawson James Securities, where he served as Director of Research and as a senior biotechnology analyst. He was previously a Managing Director and senior research analyst at Rodman & Renshaw, a Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology, and a Managing Director and senior equity analyst at Wedbush Securities. Beforehand, Mike served as a Managing Director and senior biotechnology analyst both at Merriman Curhan Ford and at Rodman & Renshaw, where, in his initial tenure with the company, he was also the Director of Research. Additionally, Mike has held senior equity research positions at Banc of America Securities, Robertson Stephens, Vector Securities and Dillon Read & Co., covering a wide range of market capitalizations and therapeutic categories. He began his career as a biotechnology specialist in the private client sales divisions of Alex. Brown & Co., Hambrecht & Quist and Kidder, Peabody & Co.

In 2013, Mike ranked first among all stock pickers in the Pharmaceuticals category in the annual “Best on the Street” analyst survey conducted by The Wall Street Journal.

Mike holds a BA in finance from The Bernard M. Baruch College of the City University of New York.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Nicholas Dracopoli, Vice President and Head of Oncology, Janssen Research & Development

Dr Nicholas Dracopoli is Vice President/Head of Oncology Biomarkers at Janssen R&D, LLC of Johnson & Johnson. In this role he is responsible for biomarker discovery, development and application for oncology products. Previously, he was Vice President of Clinical Discovery Technologies at Bristol-Myers Squibb, and prior to that spent five years in the biotechnology industry at Sequana Therapeutics. Dr Dracopoli obtained his B.Sc. and Ph.D. degrees from the University of London, and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center and the Massachusetts Institute of Technology (MIT). Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center and as a Section Chief at the National Center for Human Genome Research at the NIH before moving to the biotechnology industry. Dr Dracopoli has authored >70 scientific publications, and has extensive experience in the fields of genomics, molecular biology and cancer research.

Neil Exter, Partner, Third Rock Ventures and CBO, Blueprint Medicines

Neil Exter joined Third Rock Ventures in 2007 and plays an integral role in the overall formation, development and business strategy of our portfolio companies. Additionally, he supports the business development efforts within the portfolio companies. He also assumes active leadership roles in our portfolio companies, functioning as interim COO/CBO through the first 12-18 months post launch.

Neil has over 20 years of business development and strategic experience, facilitating the successful development and implementation of operations and collaborations across the spectrum of newly emerging and established biotech companies.

Prior to joining Third Rock Ventures, Neil was CBO of Alantos Pharmaceuticals, leading the sale of the company to Amgen. Previously, Neil served as VP for Millennium Pharmaceuticals, directing in-licensing and M&A. Earlier in his career, Neil held various executive management roles within the high technology industry, including tenures at Hewlett Packard and Wang Laboratories.

Paul Higham, CEO, immatics biotechnologies GmbH

Paul Higham was appointed as CEO of immatics in August 2008. Previously, he served as Director Commercial Development at Ark Therapeutics Group plc where he was responsible for commercial strategy and all business development activities. In addition, he was in charge of establishing the operations and gene-based medicine production facilities of Ark Therapeutics in Finland.

Prior to joining Ark Therapeutics in 2001, Paul Higham worked as International Commercial Vice President for GI, Metabolic and Pain at GlaxoWellcome plc from 1996 to 2001, where he was responsible for all aspects of business development, strategic marketing, sales and finance. From 1985 to 1996, after completing his studies in Applied Biology, he held various sales and marketing positions of increasing responsibility with Bayer AG and eventually became General Manager of Bayer Pharmaceuticals for Sweden and Denmark.

Paul Juniewicz , North American Head of Oncology Business Opportunities, Sanofi

Paul Juniewicz is currently the North American Head of Oncology Business Opportunities (OBO) within the Strategic Portfolio and Management Group of the Oncology Division for Sanofi. Within this group, Paul and his Team are responsible for scouting and evaluating external oncology opportunities and possible research collaborations and making recommendations on these external opportunities/ research collaborations to the Oncology Review Board (ORB) and other Senior Management Committees, in particular the External Working Group (EWG). The OBO Team works closely with all groups within the Oncology Division and in close collaboration with Business Development and the Strategy, External Innovation & Science Policy Department.

Prior to this current role, Paul was most recently Vice-President within the External Innovation Department of sanofi-aventis, Research + Development responsible for scouting and evaluating early research opportunities across all therapeutic areas.

Previous to that role was Vice-President Oncology Projects, Project Direction responsible for the development and registration of oncology projects including Eloxatin (oxaliplatin) and Elitek (Rasburicase).

Paul received his BS from Rutgers University, MS and PhD from North Carolina State University and conducted post-doctoral training at Johns Hopkins University. Paul joined Sterling Drug in 1987 as a research scientist and transitioned to Sanofi, Sanofi-Synthelabo, sanofi-aventis and most recently Sanofi / Genzyme.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Petter Björquist, Senior Principal Scientist and Department Head, Cellectis

Petter Björquist, Ph.D., Senior Principal Scientist and Department Head, at Cellectis Stem Cells, responsible for the areas stem cell-derived hepatocytes and beta-cells.

PB has about ten years of experience from AstraZeneca R&D, Sweden, where he was previously active in a project management team in the therapeutic area Cardiovascular Diseases. PB is the author of more than 40 scientific articles, and is today heading a team of about 15 scientists.

He is also supervising both PhD-students and postdocs, and is coordinating the major collaboration between Novo Nordisk and Cellectis on using regenerative medicine for treatment of diabetes.

Philip Gotwals, Executive Director, Oncology Research Collaborations, Novartis Institute for Biomedical Research

Philip Gotwals is currently Executive Director, Oncology Research Collaborations, responsible for overseeing global strategic research alliances in the Oncology Disease Area at Novartis Institutes of BioMedical Research. Dr. Gotwals has over 15 years of experience in the biotechnology and pharmaceutical industries managing internal and collaborative product development programs from discovery to NDA filing, and participating in the licensing of product candidates. Phil is the former Vice President, Project Management at Altus Pharmaceuticals responsible for all product development project management activities. Prior to his engagement at Altus, Phil was Senior Director, Program and Alliance Management at Biogen Idec where he oversaw management of internal and allied early product development teams in the autoimmune, neurology and oncology therapeutic areas. Dr. Gotwals holds a PhD in Genetics and Molecular Biology from the University of California at Berkeley, and finished post-doctoral research at the Massachusetts Institute of Technology.

Patrick Fortune, General Manager, Cleveland Clinic Innovations

Patrick Fortune, PhD, MBA, director, technology development and selection, is Senior General Manager of Cleveland Clinic Innovations and served as a member of CCI’s Innovation Advisory Board for 7 years prior to joining CCI. Dr. Fortune was a partner at Boston Millennia Partners for more than decade, with responsibility for investing in early stage healthcare companies. Dr. Fortune senior leadership experience in the healthcare, life sciences and information technology sectors and has nurtured start-up activities from idea to prototype to standalone business throughout his career and has taken more than 30 companies through to a monetization. He has been a senior executive at multiple Fortune 500 companies, including president and COO of New Era of Networks; corporate VP at Monsanto; VP at Bristol Myers Squibb; and group president, as well VP of R&D, at Baxter International. Dr. Fortune currently serves on the boards of directors of Parexel International Corp, a global $2.5-billion contract research organization (NASDAQ, PRXL), and several private, life sciences companies. He holds a B.A. and a PhD in physical chemistry from the University of Wisconsin, and an MBA from Northwestern University.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Rafael Amado, SVP, Head of Oncology R&D, GlaxoSmithKline

Rafael Amado’s is Senior Vice President, Oncology R&D at GlaxoSmithKline. He is accountable for integrating oncology R&D efforts from drug target identification through late-stage development and registration globally.

Rafael joined GSK in 2008 as Vice President, Medicine Development Leader. In that capacity he was responsible for developing and executing the asset’s development strategy globally. He served in positions of increasing responsibility as Vice President, Oncology Solid Tumors and Senior Vice President, Oncology Development.

Prior to joining GSK, Rafael was Executive Director in the Therapeutic Oncology Area at Amgen where he was responsible for development activities of several assets. An area of his interest is biological characterization of tumors for patient selection, which he successfully applied to targeted drug development. Rafael trained as a Hematologist/Oncologist at the University of California, Los Angeles, where he remained as faculty until joining Amgen in 2003.

Rafael has led the development of numerous small molecules and biologic products through initial registration and label extensions. A native of Spain, he holds an M.D. from the University of Seville School of Medicine. He performed his residency in Internal Medicine at Michael Reese Hospital, a University of Chicago Affiliated Hospital, and his fellowship in Hematology/Oncology at the University of California, Los Angeles. He has published extensively in his field, and is a member of the American College of Physicians, the American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research.

Punit Dhillon, Co-Founder, Director and CEO, OncoSec Medical Incorporated

Mr. Dhillon was formerly Vice President of Finance and Operations at Inovio Pharmaceuticals, Inc., until March 2011. In his corporate finance role, Mr. Dhillon was pivotal to the company raising over $125 million through multiple financings and several licensing deals including early stage deals with Merck and Wyeth. He was also instrumental to the successful in-licensing of key intellectual property and a number of corporate transactions, including the acquisition and consolidation of Inovio AS, a Norwegian DNA delivery company, and led the merger with VGX Pharmaceuticals, which solidified Inovio’s position in the DNA vaccine industry. As head of operations, he successfully completed the integration of the VGX-Inovio merger including cost-cutting of over 30% through the synergy assessment of both companies, consolidation of four operating locations in to two bi-coastal offices, corporate rebranding and management of existing shareholders from both companies. Mr. Dhillon has been a consultant and board member for several early stage life science companies. Prior to joining Inovio, Mr. Dhillon worked for a corporate finance law firm as a law clerk. Previous to 2003, he worked with MDS Capital Corp. (now Lumira Capital Corp.) as an intern analyst.

Mr. Dhillon is a mentor to the TiE Young Entrepreneurs (TYE) Program where he recently led his team of students to win the 2012 global business plan competition in Atlanta. He is an active member in his community and advocate for cancer research and advancing the availability of healthcare.

In 2012, Mr. Dhillon helped raise over $30,000 to support the British Columbia Cancer Foundation and the British Columbia Children’s Hospital through charitable contributions. He is also the co-founder of Inbalance Network Inc., a wellness organization focused on promoting an active lifestyle and grassroots community involvement, including scholarships that support students pursuing post-secondary education. Mr. Dhillon has a Bachelor of Arts with honors in Political Science and a minor in Business Administration from Simon Fraser University. He resides in San Diego, California with his wife and two daughters, and enjoys being active through competitive running, swimming and biking.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Seth Yakatan, Co-Founder, Katan Associates

Seth Yakatan brings more than 20 years of experience as a corporate finance professional, actively supporting small cap and major companies in achieving corporate, financing and asset monetization objectives through the successful structuring and management of strategic transactions and investments totaling more than several billion dollars in value.

Over the past twelve years as a co-founder of Katan Associates (KAI), Seth has successfully structured and managed strategic alliances and deals, based on his insight and expertise in the US and Global Life Science sector, including numerous buy- and sell-side M&A transactions.

Completed Life Science transactions at KAI include:• Twelve buy and sell-side M&A engagements, generating aggregate transaction value in excess of $345 million.• Numerous early-stage pharmaceutical partnering assignments with aggregate value generated for clients of more than

$875 million.• Facilitation of several royalty monetization transactions, with aggregate realized value in excess of $125 million.

Prior to founding Katan Associates in 2001, Seth worked in merchant banking at the Union Bank of California, N.A., in the Specialized Lending Media and Telecommunications Group. During his six years there, he completed the placement of subordinated debt and private equity investments, exceeding $3 billion in transaction value.

Seth began his career as a venture capital analyst with Ventana Growth Funds and Sureste Venture Management, where he gained significant experience in creating successful venture-backed life science companies.

Seth is a recognized as an expert in the valuation of life sciences companies, stemming from industry experience and academia. He has authored several publications and lectured and guest lectured at corporate workshop and universities on valuation theory and real-world practice and case studies, and consulted to several state and provincial governments worldwide on commercialization and capital access initiatives.

Seth has also served as a speaker and faculty member at industry conferences including the Annual BIO International Convention Executive Workshop Series. Seth serves as an advisor to Boston Communications, a communications consulting firm that supports business leaders in addressing their greatest communications challenges, and to The Brookwood Group, a specialized real estate and restaurant consulting firm.

Seth holds an MBA in Finance from the University of California, Irvine and a BA in History and Public Affairs from the University of Denver.

Seth enjoys being a Dad to his two children, participating in triathlons and cycling

Prof Ronit Satchi-Fainaro, Tel Aviv University

Prof. Ronit Satchi-Fainaro (Ph.D.) is Head of the Cancer Angiogenesis & Nanomedicine Lab; Associate Professor, Department of Physiology & Pharmacology, Sackler School of Medicine. Prof. Satchi-Fainaro received her Bachelor of Pharmacy from the Hebrew University, Israel (1995) and her Ph.D. from the University of London, UK (1999). She then spent two years as postdoctoral fellow at Harvard University and Children’s Hospital Boston working with Judah Folkman on novel angiogenesis-targeted nanomedicines. In 2003, she was appointed Instructor at Boston Children’s Hospital and Harvard Medical School. She joined Tel Aviv University in 2006.

She is a leader in the field of nanomedicine and angiogenesis (cancer and vascular biology). She serves as advisor to several Israeli and International biotech companies, is President of the Israeli Society for Controlled Release, and is on the editorial boards of several biological and chemical journals. She has published more than 55 papers, 12 book chapters, edited 2 books, is named inventor on 20 patents, and was awarded numerous prestigious grants and prizes, among them Fulbright, Rothschild, Wingate, Alon, Young Investigator Award of the European Association for Cancer Research, 50 most influential women in Israel (Globes, TheMarker, Forbes) and Juludan.

She has major expertise in tumor biology, tumor dormancy, angiogenesis, molecular imaging, non-invasive intravital imaging of animal models, theranostics and nanomedicines for personalized medicine. Throughout, she has maintained an interest in understanding the biological rationale for the design of nanomedicines suitable for transfer into clinical testing. Her multi-disciplinary research laboratory focuses on basic research leading to the design of highly-selective targeting molecules integrating biology, chemistry, protein engineering, molecular imaging, computational approaches, material sciences and nanotechnology to selectively guide drugs into pathological sites.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Steven Quay, CEO, Atossa Genetics

Steven C. Quay, MD, PhD, FCAP, is a board-certified anatomic pathologist, with training at The Massachusetts General Hospital, Harvard Medical School, and the Chemistry department, Massachusetts Institute of Technology, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine. Dr. Quay is a member of the American Society of Investigative Pathology, the Association of Molecular Pathology, the Society for Laboratory Automation and Screening, and the Association of Pathology Informatics.

Steven W. Young, President, Addario Lung Cancer Medical Institute

Steven W. Young has served as the president & Chief Operating Officer of the Addario Lung Cancer Medical Institute since 2008. Mr. Young prior position was Executive Director of the Multiple Myeloma Research Consortium, after having directed the launch of a number of for-profit clinical research initiatives models. Earlier still, he served as Administrative Director of the General Clinical Research Center at Mount Sinai School of Medicine and the Pediatric Clinical Research Center at Cornell University College of Medicine, both in New York City.

Steve Tregay, Founder, President and CEO, Forma Therapeutics

Prior to joining FORMA, Steve Tregay was a Managing Director for the $200M Novartis Option Fund. He led the fund’s investments in and served on the Board of Directors of FORMA Therapeutics, Adenosine Therapeutics (acquired by Clinical Data: FRX) and Cequent Pharmaceuticals (acquired by Marina Biotech: MRNA). Prior to joining the venture group, he was the Executive Director and Head of Strategic Alliances-Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team who were responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research. He received his Ph.D. and M.S. in organic chemistry from Harvard University and a B.S. from Davidson College.

Sheikh Usman Iqbal, Head of Oncology, Global Evidence & Value Development, Medical Affairs, Global R&D, Sanofi

Dr Usman Iqbal MD, MPH, MBA is the head of Oncology Global Evidence & Value Development at Sanofi, where he is responsible for developing product value for Sanofi’s oncology/hematology portfolio through strategic development, execution and translation of evidence based research throughout the lifecycle of the products. His health care experience spans clinical medicine, health policy and management, health economic & outcomes research in both academia and biopharmaceutical industry, including Amgen and Boehringer Ingelheim. Dr Iqbal has broad based experience in building value and product differentiation across multiple therapeutic areas including oncology, respiratory, rheumatology, hepatology, and mental health. Prior to working in the industry, Dr Iqbal was at the Boston University Health Outcomes Technology Group as a senior research fellow and served as a research consultant for Veterans Affairs Pharmacy Benefit Management (VA-PBM), the Centers for Medicare & Medicaid Services’ Health Outcomes Survey Initiative (CMS-HOS), the Agency for Healthcare Research and Quality (AHRQ), and the National Committee for Quality Assurance (NCQA). His research experience encompasses outcomes evaluation in large integrated health care systems and databases with a specific focus on comparative effectiveness, disease management, patients’ health related quality of life, and risk-adjustment methodologies. Dr Iqbal received his MD from Allama Iqbal Medical College, Lahore, Pakistan and Master of Public Health and Master of Business Administration from Boston University.



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Speakers

Dr Susan Love, President, Dr Susan Love Research Foundation

Susan Love MD, MBA has dedicated her professional life to the eradication of breast cancer. As President of the Dr. Susan Love Research Foundation, she oversees an active research program centered on breast cancer cause and prevention. She is also a Clinical Professor of Surgery at UCLA’s David Geffen School of Medicine.

Dr. Love received her medical degree from SUNY Downstate Medical Center in New York and did her surgical training at Boston’s Beth Israel Hospital. She founded the Faulkner Breast Center in Boston and the Revlon UCLA Breast Center in Los Angeles. She has a business degree from the Executive MBA program at UCLA’s Anderson School. In 1996 she retired from the active practice of surgery, to dedicate her time to the urgent pursuit of finding the cause and prevention of breast cancer. She has done this in the for-profit and the non-profit arena, including creating several medical device companies based on the intraductal approach to the breast.

Her reputation as an activist comes from her role as one of the “founding mothers” of the breast cancer advocacy movement in the early 1990’s. She was one of the founders of the National Breast Cancer Coalition (NBCC). She served on the National Cancer Advisory Board from 1998-2004 as an appointment of President Clinton.

Dr. Susan Love is best known as a trusted guide to women worldwide through her books and the Foundation website. The completely revised fifth edition of Dr. Susan Love’s Breast Book termed “the bible for women with breast cancer” by The New York Times was released October 2010. It has been translated into German, Dutch, Chinese, Japanese and Hebrew. Dr. Susan Love’s Menopause and Hormone Book, first published in 1998 and revised in 2003, was one of the first to sound the alarm against the long term use of postmenopausal hormones. Live a Little (Crown 2009) encourages women to take a reasonable approach to becoming healthy.

A true visionary, Susan Love’s recent projects include the Love/Avon Army of Women (through the Dr. Susan Love Research Foundation), a creative Internet solution to partner women and scientists to accelerate basic translational research. The campaign is recruiting one million women who are willing to consider participating in research to find the cause and prevention of breast cancer. This novel initiative will move research from animals to women, democratizing the scientific process. To date, over 370,000 women and men have signed up to participate. In October 2012, the Dr. Susan Love Research Foundation launched the Health of Women Study (HOW), a first of its kind, global, online cohort study focused on identifying new risk factors for breast cancer.

Timothy Herpin, VP, Strategic Partnering Business Development Oncology, Science & Trading, AstraZeneca

Timothy Herpin joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for CNS& Pain and more recently for Oncology & STL. In this role, he leads a team of business development professionals involved in all aspects of deal making for the Oncology franchise. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction execution in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacopeia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern.

Stuart Barich, Managing Director, Healthcare Investment Banking, Oppenheimer & Co.

Stuart Barich has been with Oppenheimer since September 2005 as a Managing Director focusing on Life Sciences. He has participated in the successful completion of over 150 transactions during his career covering a broad spectrum of equity and mergers and acquisitions. Prior to joining Oppenheimer, he spent five years at Leerink Swann completing numerous transactions for Biotechnology and Specialty Pharmaceutical companies. Prior to joining Leerink, he directed the healthcare banking efforts at Oscar Gruss & Son and Auerbach, and began his career as a Corporate Finance Associate with Paine Webber. Mr. Barich earned a BS in Electrical Engineering from the University of Rochester and an MBA with honors from Columbia Business School.



WELCOM

ESPEAKERS

Sachs Associates



Speakers

t back :: next u

Yong S. Chen, Senior Director, Head of Biology, Aileron Therapeutics

Yong S. Chen has served as our Head of Biology and Translational Research since April 2011 and leads cell and molecular biology, translational pharmacology, DMPK, and in vivo pharmacology. He also served as the program lead and the Alliance Manager for the collaboration with Roche. Yong joined Aileron from MedImmune, Inc. where he was the head of translational pharmacology. As one of the senior members of the Global Oncology Leadership Team and research review committee, Dr. Chang played an instrumental role in formulating strategy and direction for the departments of Oncology and Translational Sciences. He also led multiple research and translational development teams. Prior to MedImmune, he worked with Bayer Pharmaceuticals, where he held positions with increasing responsibilities and contributed to the launch of Nexavar® (sorafenib). Prior to Bayer, Dr. Chang worked at Roche Pharmaceuticals.

Dr. Chang received a B.S. in premedicine and biology and a Ph.D. in physiology from Pennsylvania State University, and was a postdoctoral research fellow at Harvard Medical School/Massachusetts General Hospital.

Tamar Raz, VP Marketing and Strategy, Ramot

Tamar serves as VP Marketing and Strategy, responsible for strategic alliances and marketing activities. Prior to assuming her current position, she was Director of Business Development at Ramot, managing business development activities for life science technologies developed at TAU.

Her Ph.D. and M.Sc. degrees were earned in the field of Embryology & Teratology from Tel Aviv University.

Prior to joining Ramot in 2004, Tamar directed the establishment of Allergene, Ltd., founded as an incubator project in 1998, and served as its CEO until the end of 2003. She established and managed corporate and academic relationships, animal models research, and pre-clinical development operations. She was also responsible for raising funds - yielding a first round investment of venture capital; corporate collaborations; contractual research relationships; and government grants..



WELCOM

ESPEAKERS

Sachs Associates



Aileron Therapeutics, Inc. www.aileronrx.com

ADDRESS 281 Albany StreetCambridge, MA 02139

TELEPHONE 617-995-0900

FAX 617-995-2410

EMAIL [email protected]

YEAR FOUNDED2001

COMPANY PROFILE

Aileron Therapeutics is creating one of the first new classes of drugs in 20 years. Our proprietary Stapled Peptide drugs uniquely capitalize on 25 years of genetic research to attack the key drivers of complex diseases such as cancer, metabolic and endocrine conditions and inflammation. By harnessing one of the most common, but elusive, structures in nature - the alpha helical peptide, we believe that we can dramatically improve the treatment of these diseases and positively impact the lives of millions of patients. For more information, please visit www.aileronrx.com.

MANAGEMENT

Joseph A. Yanchik III, President and Chief Executive OfficerD. Allen Annis, Ph.D., Vice President, Biophysical and Analytical TechnologiesYong S. Chang, Ph.D., Senior Director, Head of BiologyHubert C. Chen, M.D., Vice President, Clinical Development, Endocrine and Metabolic DiseaseHuw M. Nash, Ph.D., Vice President, Corporate DevelopmentTomi K. Sawyer, Ph.D., Chief Scientific Officer, SVP Discovery & Innovative Technologies

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



AnaptysBio, Inc. www.anaptysbio.com

CONTACTSHamza Suria President & CEO

Cindy Stewart Executive Admin.

ADDRESS 10421 Pacific Center CourtSuite 200San Diego, CA 92121

TELEPHONE858-362-6295

FAX858-362-6296

EMAIL [email protected] [email protected]

YEAR FOUNDED2005

COMPANY PROFILE

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. AnaptysBio’s proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. The Company has previously announced pharma partnerships with Merck, Roche, Novartis, Celgene, Gilead and DARPA. Major investors in AnaptysBio include Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo A/S. For more information, visit www.anaptysbio.com.

MANAGEMENT

Hamza Suria, President & CEO

David King, Chief Scientific Officer

Chuck Covington, Head of Finance

t back :: next u



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Argos Therepeutics, Inc. www.argostherapeutics.com

CONTACTSInvestors & Partnering Jeff Abbey CEO and President

Media The Ruth Group Caitlin Cox

ADDRESS 7233 Technology DriveDurham, North Carolina 27704

TELEPHONE(919) 287-6300

FAX919-287-6336


YEAR FOUNDED1997

COMPANY PROFILE

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos´ most advanced product candidate AGS-003 has initiated a Phase 3 study for the treatment of mRCC, and the Company plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in late 2013. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

MANAGEMENT

Jeffrey Abbey, President, Chief Executive Officer

Frederick Miesowicz, Chief Operating Officer

Charles Nicolette, Chief Scientific Officer, Vice President of Research and Development

Lori Harrelson, Vice President, Finance

Doug Plessinger, Vice President, Clinical and Medical Affairs



WELCOM

ESPEAKERS

Sachs Associates



Atossa Genetics www.atossagenetics.com

CONTACTSSPEAKER Steven C. Quay, MD, PhD, FCAP CEO and President, Atossa Genetics, Inc. andDirector, National Reference Laboratory for Breast Health, Inc.

Taryn Frazier, Executive Assistant, Atossa Genetics

Matthew Haines, Managing Director, MBS Value Partners

ADDRESS 4105 E Madison St, Suite 320 Seattle, WA 98112

TELEPHONE Steven Quay 800-351-3902 ext 111

FAX 1-206-430-1288


YEAR FOUNDED2009

FINANCIAL SUMMARY

Net loss for the year ended 12/31/12: $5.1 million, or $(0.41) per share.

Revenues for the 12 months ended 12/31/12: $481,842, which included $6,440 of product revenue from the sale of MASCT Systems and $475,402 of diagnostic testing service revenue from the ForeCYTE and ArgusCYTE breast health tests.

Gross profit for the 12 months ended 12/31/12: $416,213.

Cash at 12/31/12: $1.7 million

COMPANY PROFILE

Atossa Genetics is a healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic medical devices and laboratory developed tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions and ductal carcinoma in situ, or DCIS. The Company’s leading diagnostic test, the ForeCYTE Breast Health Test, consists of a patented medical device that can collect fluid samples from the breast milk ducts, where over 95% of breast cancers arise. These samples are processed at Atossa’s wholly-owned, CLIA-certified, National Reference Laboratory for Breast Health, and a report is generated for the doctor and patient. The ForeCYTE Test was launched in January 2013 through Clarity Women’s Health and major medical device distributors who collectively have 5,000 sales reps calling on 33,000 OB/GYNs nationwide. Atossa also offers the ArgusCYTE Breast Health Test, a test to detect circulating breast tumor cells in patients who have been treated for breast cancer. For additional information, visit www.atossagenetics.com.

MANAGEMENT

Steven C. Quay, M.D., Ph.D. Dr. Quay has served as Chief Executive Officer and Chairman of the Board of Directors of the Company since the Company was incorporated in April 2009. Prior to his work at the Company, Dr. Quay served as Chairman of the Board, President and Chief Executive Officer of MDRNA, Inc., a biotechnology company focused on the development and commercialization of RNAi-based therapeutic products, from August 2000 to May 2008, and as its Chief Scientific Officer until November 30, 2008 (MDRNA, Inc. was formerly known as Nastech Pharmaceutical Company Inc. and is currently known as Marina Biotech, Inc.). From December 2008 to April 2009, Dr. Quay was involved in acquiring the Company’s assets and preparing the Company’s business plan. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at the Massachusetts General Hospital, a Harvard Medical School teaching hospital, is a former faculty member of the Department of Pathology, Stanford University School of Medicine, and is a named inventor on 14 U.S. and foreign patents covering the MASCT System. He oversaw the clinical testing and regulatory filing of the MASCT device with the FDA that led to its ultimate marketing clearance. Including the patents for the MASCT System, Dr. Quay has a total of 76 U.S. patents, 108 pending patent applications and is a named inventor on patents covering five pharmaceutical products that have been approved by the FDA. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan Medical School. He also received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. Dr. Quay is a member of the American Society of Investigative Pathology, the Association of Molecular Pathology, the Society for Laboratory Automation and Screening and the Association of Pathology Informatics. He was selected to serve on the Company’s Board of Directors because of his role as the founder of the Company and the inventor of the MASCT System, as well as his qualifications as a physician and the principal researcher overseeing the clinical and regulatory development of the MASCT System.

Kyle Guse, Esq., CPA. Mr. Guse has served as Chief Financial Officer, General Counsel and Secretary since January 2013. His experience includes more than 20 years of counseling life sciences and other rapid growth companies through all aspects of finance, corporate governance, securities laws and commercialization. Mr. Guse has practiced law

Continued...

t back :: next u



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Atossa Genetics www.atossagenetics.com

CONTACTSSPEAKER Steven C. Quay, MD, PhD, FCAP CEO and President, Atossa Genetics, Inc. andDirector, National Reference Laboratory for Breast Health, Inc.

Taryn Frazier, Executive Assistant, Atossa Genetics

Matthew Haines, Managing Director, MBS Value Partners

ADDRESS 4105 E Madison St, Suite 320 Seattle, WA 98112

TELEPHONE Steven Quay 800-351-3902 ext 111

FAX 1-206-430-1288


YEAR FOUNDED2009

at several of the largest international law firms, including from January 2012 through January 2013 as a partner at Baker Botts LLP and, prior to that, from October 2007 to January 2012, as a partner at McDermott Will & Emery LLP. Before working at McDermott Will & Emery, Mr. Guse previously served as a partner at Heller Ehrman LLP. Mr. Guse began his career as an accountant at Deloitte & Touche and he is a licensed Certified Public Accountant in the state of California. Mr. Guse earned a B.S. in Business Administration and an M.B.A. from California State University, Sacramento, and a J.D. from Santa Clara University School of Law.

Shu-Chih Chen, Ph.D. Dr. Chen has served as Chief Scientific Officer and director of the Company since the Company was incorporated in April 2009. Prior to joining the Company, Dr. Chen served as President of Ensisheim beginning in 2008, was founder and President of SC2Q Consulting Company from 2006 to 2008, and served as Head, Cell Biology, Nastech Pharmaceuticals Company, Inc. from 2002 to 2006. During 1995 and 1996, she was an Associate Professor at National Yang Ming University, Taipei, Taiwan, and served as the principal investigator of an NIH RO1 grant studying tumor suppression by gap junction protein connexin 43 at the Department of Molecular Medicine at Northwest Hospital before working in the research department at Nastech Pharmaceutical Company. She is named as an inventor on four patent applications related to cancer therapeutics. Dr. Chen received her Ph.D. degree in microbiology and public health from Michigan State University in 1992 and has published extensively on Molecular Oncology. She received her B.S. degree in medical technology from National Yang Ming University, Taipei, Taiwan in 1984. Dr. Chen was selected to serve on the Company’s Board of Directors because of her qualifications in medical technology and as a professor and researcher in the field of cancer therapeutics.

...continued



WELCOM

ESPEAKERS

Sachs Associates



BioCancell Ltd. www.biocancell.com

CONTACTJonathan Burgin CEO

ADDRESS 8 Hartom Street P.O.B 45382 Jerusalem, Israel 91451

TELEPHONE 972-2-5486555

FAX 972-2-5486550


YEAR FOUNDED2004

COMPANY PROFILE

BioCancell is dedicated to developing cancer treatments suitable for over 40 types of cancer, including pancreatic cancer, bladder cancer and ovarian cancer. BioCancell’s patented, personalized cancer therapy approach is based on the identification of target oncogenes, such as H19. It aims to provide alternative cancer treatments that offer strong therapeutic efficacy combined with a lack of side effects.

The first cancer treatment utilizing H19, designated BC-819, works to destroy cancerous cells only. BC-819 is in the clinical trial stage for treatment of pancreatic cancer, bladder cancer and ovarian cancer. It has also been tested in compassionate use trials for liver cancer and kidney TCC. Clinical results have shown effectiveness in removing existing cancerous growths and keeping patients clear of new growths.

MANAGEMENT

Jonathan Burgin, CEOProf. Avraham Hochberg, Chief ScientistMonique Ben-Am, VP Clinical TrialsMichal Gilon, VP R&D

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



BioLineRx Ltd. www.biolinerx.com

CONTACTBioLineRx Ltd. [email protected]

ADDRESS 19 Hartum St. POB 45158 Jerusalem 9777518 Israel

TELEPHONE + 972 + 2 + 5489100

FAX + 972 + 2 + 5489101


YEAR FOUNDED 2003

COMPANY PROFILE

Founded in 2003 by Teva Pharmaceuticals and other leaders in the Israeli life sciences arena, BioLineRx Ltd. is a biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies.

BioLineRx’s business model is based on acquiring molecules, mainly from academic institutions, and developing them to the stage of proof of concept in humans.

The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development and commercialization.

BioLineRx currently has 7 compounds in clinical development stage, and 5 project undergoing preclinical development.

MANAGEMENT

Kinneret Savitsky, PhD, Chief Executive OfficerPhilip Serlin, CPA, MBA, Chief Financial and Operating OfficerMoshe Phillip, MD, VP, Clinical/Medical Affairs and Senior Clinical AdvisorLeah Klapper, PhD, General Manager, BIJDavid Malek, MBA, VP, Business Development

t back :: next u



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



Cellectis www.cellectis.com

ADDRESS Cellectis 8 rue de la Croix Jarry 75013 Paris France

TELEPHONE +33 (0)1 81 69 16 00

FAX +33 (0)1 81 69 16 06


YEAR FOUNDED1999

FINANCIAL SUMMARY

Incorporated: January 2000

Stock exchange: Alternext by NYSE-Euronext, Paris

Ticker code: ALCLS

ISIN code: FR0010425595

Number of outstanding shares: 20.434.714

Listing date: February, 7 2007

Activity: Cellectis develops high-precision, high-performance systems for DNA surgery and cell reprogramming.

COMPANY PROFILE

Founded in France in 1999, the Cellectis Group runs on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bio-energies. Leading the field of pluripotent stem cells, Cellectis has developed expertise in drug discovery, the study of drug toxicity and regenerative medicine. Co-initiated by André Choulika, its Chairman and Chief Executive Officer, Cellectis is now one of the world’s leading companies in the field of genome engineering, with revenue of €21 million in 2012. Cellectis has a workforce of 230 employees working at 5 sites worldwide: Paris & Evry in France, Gothenburg in Sweden, New Brighton (Minnesota) & Cambridge (Massachusetts) in the United States. The Group has signed more than 100 industry agreements with pharmaceutical, agrochemical, and biotechnology companies. University College of London (UCL), the National Institute of Health (NIH), Novo Nordisk, The Center for iPS Cell Research and Application (CiRA), AFM, Novartis, BASF, Bayer, and Limagrain are some of the Group’s clients and partners. Since 2007, Cellectis has been listed on the NYSE Euronext Alternext market (code: ALCLS) in Paris.

MANAGEMENT

The Company is a French “Société Anonyme” (SA) with a Board of Directors. The CEO, Dr André Choulika, leads the company’s management structure. He supervises the sales policy and research and development strategy, and ensures the coordination between the Group’s various management structures. An executive committee assists him. This committee is a driving force in the management of operations and current business, as well as in company strategy.



WELCOM

ESPEAKERS

Sachs Associates



CENTROSE www.centrosepharma.com

CONTACTDr James Prudent President and CEO

ADDRESS 802 Deming Way Madison, WI 53717

TELEPHONE 608-836-0207 608-209-8933


YEAR FOUNDED2007

FINANCIAL SUMMARY

Funding to Date

Dilutive: $5,600,000

Non-dilutive: $2,100,000

COMPANY PROFILE

Centrose is a biopharmaceutical company that discovered a patented process to build the next generation of drug conjugates. The Centrose drug pipeline currently includes 7 drug candidates that address markets exceeding $20 Billion. Currently there are only 2 approved drug conjugates owned by two companies, both with market values above $1 Billion. Market potential for Centrose post FDA approval then could approach 30X post round. Centrose estimates Phase I clinical trials to cost $15 Million and take 3 years.

Centrose is seeking $20 Million. Post offering, Centrose would have 37 million outstanding shares valued at $1.50 / share.

For more in depth information please see the Centrose website and request the 2013 Centrose Business Plan by emailing or calling Dr. Prudent.

MANAGEMENT

Centrose management knows how disease can devastate people’s lives and how to bring advanced biopharmaceuticals to market. We are all dedicated to making a difference. The Board of Directors have all started and sold successful Life Science Companies and the management team have all launched multiple biotechnology products. Together, this team has been associated with 7 successfully acquired biotechnology companies with Pharmasset the largest and selling for $11 Billion.

The management team includes; Dr. Ray Schinazi, Dr. Troy Wilson, Dr. Jon Thorson, Mr. Hayden Leason, Dr. Mohammed Shekhani, Mr. David Marshall and Dr. James Prudent.

Advisors to Centrose include: Dr. Homer Pearce, Mr. Kevin Kaster, Dr. Paul Anderson, Dr. Gary Ward and Dr. Stan Roberts.

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



Churchill Pharmaceuticals www.churchillpharma.com

CONTACTSMatt Callahan President and CEO

Maurits Geerlings

Maurice Hampton

ADDRESS One Kew Place 150 Rouse Boulevard Navy Yard Corporate Center Philadelphia, PA 19112



YEAR FOUNDED2005

COMPANY PROFILE

Churchill Pharmaceuticals LLC (“Churchill”) is a Philadelphia based company developing improved orally administered cancer products.

During the 2013 Sachs Cancer Bio Partnering Forum, Churchill Pharmaceuticals is offering the following partnering opportunities:

• Life-cycle management for existing marketed or late-development stage orally administered cancer drugs

• In-licensing of NCEs with strongly established proof of concept, where solubility and bioavailability has been a barrier to further clinical development

Churchill utilizes a novel technology known as SoluMatrix™, to reduce the average size of drug particles down to the sub-micron-scale. These drug particles can be rapidly and completely absorbed, thereby significantly increasing bioavailability and reducing the potential harmful effects of food. While reducing the high variability in absorption, Solumatrix™ may improve the clinical efficacy and safety profile of orally administered drugs. The Solumatrix™ technology has been designed to offer a rapid and cost effective clinical path –leading to a 505(b)(2) NDA – and approval of improved products. These medicines can be made available to patients in a much shorter timeframe and at significantly less development cost.

MANAGEMENT

Matt Callahan, President and CEODr. Bill Bosch, Chief Scientific Officer t

back :: next u



WELCOM

ESPEAKERS

Sachs Associates



Constellation Pharmaceuticals www.constellationpharma.com

CONTACTDeb Drouin

ADDRESS Constellation Pharmaceuticals 215 First Street Cambridge, MA 02142

TELEPHONE Office: 617-714-0555

Deb Drouin 617-714-0525

FAX 617-577-0472

EMAIL Matthias.jaffe @constellationpharma.com Deb.drouin @constellationpharma.com

YEAR FOUNDED2008

FINANCIAL SUMMARY

Private company.

COMPANY PROFILE

Constellation is focused on the discovery and development of small molecule therapeutics that modulate chromatin to treat cancer and inflammatory/immunologic disorders. Chromatin modifiers target the enzymes and binding proteins that act as a cell’s toolkit for epigenetic regulation and help control when and where genes are expressed. When abnormal epigenetic regulatory events occur, the proteins that regulate these events can become drivers of disease. The Company’s approach to treating cancer and inflammatory diseases is to inhibit these targets through chromatin modulation. The Company is in a pre-clinical stage of development. Three programs are underway: two “BET” programs, addressing cancer and immunology/inflammatory disease and one “EZH2” program focused on cancer.

MANAGEMENT

Keith E. Dionne, President and CEOMatthias Jaffe, CFOJim Audia, CSOMike Cooper, CMOBrenda Sousa, VP HR

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



CureVac GmbH www.curevac.de

CONTACTDr Ingmar Hoerr, MBA Chief Executive Officer

ADDRESS CureVac GmbH Paul-Ehrlich-Str. 15 72076 Tuebingen Germany

TELEPHONE +49 (0) 7071-9205320

FAX +49 (0) 7071-9205311


YEAR FOUNDED2000

FINANCIAL SUMMARY

CureVac has raised approximately €145 million in equity financing, the great majority from its main investor dievini Hopp BioTech Holding. The financing of €80 million in 2012 is one of the largest private biotech financing rounds in Europe and provides sufficient capital to advance the ongoing programs through the next few years.

COMPANY PROFILE

CureVac is developing an entirely novel class of therapies based on a fundamental new understanding of the medical potential of messenger RNA (mRNA). nCureVac aims to use this new class of therapeutics novel mRNA vaccines and adjuvants based on long, non-coding RNAs, to transform the treatment of oncological diseases and the prophylaxis for infectious diseases.

Vaccine development CureVac develops mRNA-molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases based on its proprietary technology (RNActive®).

Adjuvant development CureVac has developed RNAdjuvant® that enhances the immune response to a large number of different vaccines, including protein- and peptide based vaccines without toxic effects.

Production technology CureVac has built the first worldwide facility for manufacturing mRNA in large quantities.

MANAGEMENT

Ingmar Hoerr, PhD, MBA, CEOFlorian von der Muelbe, PhD, MBA, COOOliver Schlueter, PhD, MBA, CFODr. Franz-Werner Haas, LL.M., CCO

Board of DirectorsFriedrich v. Bohlen, PhD, ChairmanWolfgang Hartwig, PhDMatthias Hothum, PhDChristof Hettich, LLD

Scientific Advisory BoardWolfgang Hartwig, PhDAlexander Knuth, MDGiorgio Parmiani, MDHans-Georg Rammensee, PhDCaetano Reis e Sousa, DphilThomas Wölfel, MDAngus Dalgleish, MDGerd Zettlmeissl, PhDRalf Clemens, MD, PhD

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



CONTACTDouglas M Fambrough

ADDRESS 480 Arsenal St Building 1, Suite 120 Watertown, MA 02472

TELEPHONE 617 621 8097

FAX 617 252 0927


YEAR FOUNDED2007

COMPANY PROFILE

Dicerna Pharmaceuticals is a leading developer of RNA interference (RNAi) drugs targeting unmet needs in cancer. Dicerna’s promising new therapeutic approach utilizes its patented Dicer Substrate siRNA (DsiRNA™) molecules and EnCore™ drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for oncology patients.

RNAi is a naturally occurring biological process utilized by cells to regulate and silence gene expression at the RNA level. RNAi has potency that goes far beyond the potency of traditional drug technologies, enabling the effective use of oligonucleotide-based, gene-directed drugs in oncology for the first time. In addition, RNAi is gene specific, allowing maximal therapeutic effect and minimal off-target side effects.

Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

Using DsiRNAs against key driver oncogenes, delivered via EnCore, Dicerna has achieved strong anti-tumor efficacy in multiple preclinical models. Dicerna’s lead program, DCR-M1711 is focused on Hepatocellular Carcinoma (HCC) and is directed at the MYC oncogene, a key regulator of oncogenic pathways that has been implicated in multiple cancer types. Dicerna expects to file an IND to enter human clinical trials in late 2013. The company has additional programs in earlier stages of development..

MANAGEMENT

Douglas M. Fambrough, CEO

Dicerna Pharmaceuticals www.dicerna.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



Etubics Corporation www.etubics.com

CONTACTKimberly French Director, Corporate Development

ADDRESS Etubics Corporation 410 West Harrison Street Suite 100 Seattle, Wash. 98119

TELEPHONE Office: (206) 838-5110

Kimberly Jones (206) 838-5110 ext 110

FAX (206) 838-2978


YEAR FOUNDED2006

FINANCIAL SUMMARY

The Company’s product development efforts to date have been funded mainly by over $16 million in non-dilutive grants and contracts received from various government agencies. The Company is presently raising $15 million in its first institutional round to fund the Phase IIb ETBX-011 clinical trial, advance additional products to clinical trials, and fulfill working capital requirements.

COMPANY PROFILE

Etubics Corporation is a clinical stage bio-pharmaceutical company which has developed a proprietary vector based immunization platform technology, the Etubics Platform. Etubics’ stealth delivery platform induces both arms of the immune system – cell mediated immunity (“CMI”) and antibodies. The simple-to-use injectable induces a long lasting, active immune response against both cancers and infectious diseases.

Etubics has completed Phase I/Phase II clinical trials with its lead product, ETBX-011, an immunotherapeutic to treat advanced-stage metastatic colorectal cancer. To date, Etubics is encouraged by the clinical outcome for ETBX-011, as no safety issues or serious adverse effects have been reported and patients treated with EBTX-011 have a median overall survival of 11 months. The ETBX-011 pre-clinical and Phase I/Phase II clinical trials were funded by grants and contracts from the National Cancer Institute. Etubics has met with the FDA and been approved to enter a controlled, randomized Phase IIb clinical trial in 2013.

Duke University and Etubics have received $16 million from the Department of Defense to move a breast cancer immunotherapy targeting HER3 into clinical trials. Etubics is developing a separate breast cancer immunotherapy targeting HER2.

Etubics is ready to enter clinical trials for an HPV induced cancer immunotherapeutic and is currently seeking NCI funding for this project. Etubics is looking for a partner to assist with bringing this product through clinical trials.

Adenovirus vector delivery use has sparked recent interest among major pharmaceutical companies. Despite recent failures of first generation Ad5 vectors, there are continued attempts to make adenoviruses vectors succeed.

The problem is that first generation adenoviral vectors are recognized as foreign entities by the immune system, which leads to an immunologic clearance of the vaccine vector before it can become functional. The Etubics Platform is stealth to the immune system and successfully delivers immunogenic disease-specific response in both Ad naive and Ad immune patients and animals.

Etubics believes that ETBX-011 will compete with existing products such as monoclonal antibody and kinase inhibitor based regimens in mCRC patients as ETBX-011 has:

• Promising Survival Data: Median survival of 11 months, with 45% of patients surviving at 12 months and 30% alive at 18 month.

• Effective in the Presence of Pre-Existing Adenovirus Immunity. Patients demonstrated CMI, despite high levels of Ad immunity. Immune responses can also be boosted in patients.

• Safe and Easy to Use: No harsh side effects have been seen. The Etubics Platform is also a simple to use injectable with no adjuvant required.

• Long Lasting: The Etubics Platform induces a potent, long lasting and protective immune response.

• Easy to Manufacture

MANAGEMENT

Dr Frank R. Jones, Founder, Chairman, CEO, CSO • 20 years public and private Biotech Founder, CEO and CSO experience • Founded IMRE Corporation

Elizabeth Gabitzsch, Vice President, Research• Author of publications describing the Company’s technology • Scientific presentations nationally and internationally

Joseph P. Balint, Ph.D., Laboratory Operations Director• 20 years experience taking products from the bench to the bedside • IMRE Corporation

Kimberly French, Director, Corporate Development• Investor relations and partnership development • Vast fundraising experience for non-profits and start ups

Scientific Advisory Board: H. Kim Lyerly, Duke University; Andy Amalfitano, Michigan State University; Dusty Miller, Fred Hutchinson Cancer Research Center; Jim Mulé, Moffitt Cancer Center; John Lee, University of South Dakota

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



Genisphere LLC www.genisphere.com

CONTACTSBob Getts CSO

John Simons Partner

ADDRESS 2801 Sterling Drive Hatfield, PA 19440 USA

TELEPHONE (215) 996-3002

FAX (215) 996-3070


YEAR FOUNDED2009

FINANCIAL SUMMARY

Genisphere LLC is a privately held company.

COMPANY PROFILE

Genisphere is a life science company with unique, IP-protected, DNA dendrimer nanotechnology for the biomedical research, diagnostic and pharmaceutical markets. Genisphere has successfully out-licensed several reagent kits to the research market, and customizes its 3DNA nanotechnology to enable commercialization of high-sensitivity lateral flow point-of-care tests, giving a competitive advantage to partners in the diagnostic space.

Genisphere has adapted its 3DNA dendrimer technology to offer a robust alternative nanocarrier for delivering small drug, RNAi and gene construct therapeutics in a highly efficient targeted strategy. The nanoparticle is biocompatible, multivalent for both targeting and therapeutic cargo, easily adaptable, and stable in circulation. In addition to developing drug candidates, Genisphere seeks partnerships with pharmaceutical and other commercial institutions.

MANAGEMENT Corporate Fuel Partnersandhttp://genisphere.com/about-us

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



CONTACTSPaul Higham Chief Executive Officer

Assistant Claudia Biesinger

ADDRESS Paul-Ehrlich-Str. 15 72076 Tuebingen, Germany

TELEPHONE +49 7071 5397-0

FAX +49 7071 5397-900


YEAR FOUNDED2000

FINANCIAL SUMMARY

2004/2005: €14 mn Series A 2007: €40 mn Series B2010: €54 mn Series CNon equity funding total: €6 mn

Investors: • dievini Hopp BioTech holding (Dietmar Hopp) • Wellington Partners • MIG • Athos (Andreas & Thomas Strüngmann) • L-Bank • Grazia Equity • EMBL Ventures • Vinci Capital/Renaissance • KfW • NTEC • Merifin Capital

COMPANY PROFILE

immatics biotechnologies is a clinical-stagebiopharmaceutical company developing advanced therapeutic vaccines that are active against cancer. immatics’ lead product, IMA901, is in a pivotal phase 3 study after completing a successful randomized phase 2 trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, which has reported improved overall survival data in patients with advanced colorectal cancer (phase 1/2 study completed), and IMA950, which is in phase 1 in patients with glioma.

immatics is based in Tuebingen and Martinsried (Munich), Germany and has currently 72 employees (FTE).

MANAGEMENT Paul Higham, Chief Executive OfficerHarpreet Singh, Chief Scientific Officer Carsten Reinhardt, Chief Medical Officer Rainer Kramer, Chief Business Officer

immatics biotechnologies GmbH www.immatics.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



CONTACTSPeter Williams Business Development

Carol Hausner Investor Relations

ADDRESS 830 Winter Street Waltham, MA 02451


FAX 781-895-0611


YEAR FOUNDED1981

FINANCIAL SUMMARY

A summary of ImmunoGen, Inc’s latest financial information is available on the company’s website, www.immunogen.com under Investor Information.

COMPANY PROFILE

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s Targeted Antibody Payload (TAP) technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen’s highly potent cancer cell-killing agents specifically to tumor cells. The most advanced compound using ImmunoGen’s TAP technology, Kadcyla™, has been approved for marketing in the US and Switzerland, and is undergoing regulatory review in the European Union and Japan. Kadcyla is being commercialized in the US by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

MANAGEMENT Daniel Junius, President and CEOJohn Lambert, PhD, EVP and Chief Scientific OfficerCharles Morris, MB, ChB, MRCP, EVP and Chief Development OfficerGregory Perry, EVP and Chief Financial OfficerGodfrey Amphlett, PhD, VP, Process and Analytical DevelopmentCraig Barrows, VP, General Counsel and SecretaryRobert Lutz, PhD, VP, Translational Research and DevelopmentJames O’Leary, MD, VP and Chief Medical OfficerPeter Williams, VP, Business DevelopmentTheresa Wingrove, PhD, VP, Regulatory Affairs

ImmunoGen, Inc. www.immunogen.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



Life Science Nation http://lifesciencenation.com

CONTACTSAlejandro Zamorano VP of Business Development

Brian Gajewski VP of Sales

Dennis Ford CEO

ADDRESS 9B Hamilton Place Boston, MA 02108

TELEPHONE 617 600 3064

Alejandro Zamorano 617.600.0669

Brian Gajewski 617.600.0670

Dennis Ford 617.600.3064


YEAR FOUNDED2012

COMPANY PROFILE

Life Science Nation (LSN) is a sourcing platform for market intelligence and prospect pipeline development in the life science arena. LSN enables life science professionals to generate a list of qualified global targets that are a fit for their company’s products, services, and fundraising efforts. The ability to generate these Global Target Lists (GTLs) makes life science professionals more effective and efficient.

Finding the right people, products, and services in the life science arena is a conundrum – one that is made more difficult by the lack of resources to help professionals take advantage of the larger global market rather than focus regionally. The LSN platform addresses this issue by providing sales, marketing, business development, and fundraising professionals unprecedented access to the new and existing life science companies around the globe.

MANAGEMENT Dennis Ford, CEO

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



CONTACTSEric Risser Vice President, Business Development

Assistant Nya Small

ADDRESS 9640 Medical Center Drive Rockville, MD 20850


FAX 301-251-5321


YEAR FOUNDED2000

COMPANY PROFILE

MacroGenics is a private, venture-backed biotechnology company focused on the discovery, development and delivery to patients of novel biologics for treatment of cancer, autoimmune disorders and infectious diseases. Its two lead clinical programs are MGAH22 (anti-HER2) and MGA271 (anti-B7-H3), both oncology therapeutics being studied in Phase 1 clinical trials. MacroGenics has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics’ proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bi-specific technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibodydependent effector cell function. The company has multiple research and development collaborations with major pharmaceutical companies including Boehringer Ingelheim, Les Laboratoires Servier and Pfizer, Inc. For more information, visit www.macrogenics.com.

MacroGenics, Inc. www.macrogenics.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



Melanovous Oncology www.melanovus.com

CONTACTTony Brazzale VP Product & Business Development

ADDRESS 2301 NE Savannah Rd. #528, Jensen Beach, Florida 34958


Tony Brazzale +1 561-346-0307


YEAR FOUNDED2012

FINANCIAL SUMMARY

Melanovus is currently pre-revenue. The global market potential for products to treat melanoma could exceed $7.5 billion in 2015 according to Med Track 2011 projections. Sales in the U.S. could exceed $3 billion.

COMPANY PROFILE

Melanovus Oncology is a privately held, late pre-clinical stage company focused on discovering, developing and commercializing innovative new therapies and diagnostics for late stage melanoma and other skin cancers. Founded in early 2012, the company’s portfolio uses a multi-faceted approach to address treatment, identification, and prevention of melanoma, and includes compounds with demonstrated pre-clinical activity in various stages of melanoma. These first-in-class compounds are known as Multi-Target Inhibitors™ (MTIs) due to their unique ability to selectively inhibit multiple pathways expressed in melanoma with a single agent. They are highly differentiated by their activity against the AKT3 pathway, which has been described as a “master switch” in melanoma development and progression.

MANAGEMENT

Thomas Lytle, CEOPeter Gordon, CFOGavin Robertson, Ph.D., CSORogerio Neves, MD, CMOTony Brazzale, VP Product & Business Development t

back :: next u



WELCOM

ESPEAKERS

Sachs Associates



CONTACTSMr Robert Habib Chief Executive Officer

Prof Nagy Habib Chief Medical Officer

ADDRESS 1 Vincent Square London SW1P 2PN United Kingdom

TELEPHONE +1 917 455 3503

FAX 250-386-3777


YEAR FOUNDED2008

FINANCIAL SUMMARY

$400k angel investment made in 2012.

Prof Habib awarded $3m grant from Qatar Biomedical Research Institute to conduct Phase 1 study in liver cancer.

COMPANY PROFILE

MiNA Therapeutics is designing short RNA to selectively activate key genes in major disease pathways. A broad collaboration of 18 scientists and clinicians at the world’s top institutions is leveraging our proprietary design algorithm to activate genes in oncology, diabetes and morbid obesity.

MiNA’s lead candidate, currently in Phase 1 development, targets activation of the CEBPA gene for improved liver function in liver cancer. In an animal model we demonstrated 200% increase in serum albumin and 80% reduction in tumour burden whilst lowering toxicity.

In vitro work has demonstrated the candidate’s dramatic potential in cancer lines overexpressing the MYC oncogene including lung, prostate, pancreas, leukaemia, lymphoma and glioblastoma.

MANAGEMENT

Robert Habib, Chief Executive OfficerProf Nagy Habib, Chief Medical Officer

MiNA Therapeutics www.minatx.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



CONTACTDan Snyder President and COO

Katherine Clock Marketing Program Mgr.

ADDRESS MolecularMD 1341 SW Custer Drive Portland, OR 97219


FAX 503-459-4976


COMPANY PROFILE

MolecularMD provides innovative and reliable molecular diagnostics products and services to support clinical development, regulatory approval, and commercialization of targeted cancer therapies.

Using both gold-standard and cutting-edge platforms, we design sensitive, specific, standardized assays that provide robust, reproducible results in an expeditious manner appropriate for decision-making by clinical investigators, sponsors, community physicians and patients.

At MolecularMD we are committed to accelerating the pace of targeted therapy development and personalizing medicine for cancer patients.

MANAGEMENT

Dan Snyder, President and COOChad Galderisi, D.O., Vice President of Medical AffairsNasry Yassa, Vice President of Operations Jin Li, Ph.D., Research Director of Advanced DiagnosticsInger Larsen, MBA, Director of Business Development (East)Patrick Jackle, Director of Business Development (West)Sabita Sankar, Ph.D., Scientific Affairs Liaison (West)Cindy Spittle, Ph.D., Scientific Affairs Liaison (East)Katherine Clock, Marketing Program ManagerGreg Cox, Ph.D., Licensing Manager Courtney Fuller, Director of Client ServicesKim Anoe, MB (ASCP), Technical Supervisor, Clinical LaboratoryStaci McAdams, Director, Development ProgramThomas D. Yager, Ph.D., Lead IVD ScientistKevin Hawkins, Director of Quality and Regulatory Affairs

MolecularMD www.molecularmd.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



ADDRESS 14405 Walters Road, Suite 780 Houston, Texas 77014

TELEPHONE (281) 402-3167

FAX (281) 698-2070


FINANCIAL SUMMARY

Oncolix requires $20 million over the next three years to achieve the following milestones:• Phase I trial in platinum-resistant ovarian cancer as a monotherapy • Obtain orphan status in the US, Europe and Japan• Complete preclinical development for endometrial cancer with MD Anderson• Phase IIa trial in platinum-resistant ovarian cancer as a monotherapy• Optimize manufacturing and prepare CMC documentation• Phase IIb trial in platinum-resistant ovarian cancer as a monotherapy• Phase I/IIa trial in combination with chemotherapy

COMPANY PROFILE

Oncolix is a clinical-stage biotechnology company focused on cancer. The Company’s primary focus is developing ProlantaTM for Ovarian Cancer (OC).

Unmet Medical Needs: In the United States, 22,000 new OC patients are diagnosed each year and 14,000 women die of this deadly disease. While the five-year survival rate is 75% when diagnosed in an early stage, once the disease has spread, five year survival is reduced to 20%. Most women are diagnosed after the disease has spread. The current standard for treatment consists of carboplatin and paclitaxel. Renal toxicity, nausea, neuromotor toxicity, cardiovascular events, neutropenia, thrombocytopenia and anemia occur in up to 90% of patients using carboplatin and paclitaxel. There are no targeted therapies approved for OC in the United States.

Solution: Oncolix is developing a novel therapeutic protein (Prolanta). Prolanta targets prolactin receptors, which are found in gynecological cancers, including OC, endometrial cancer and breast cancer (BC). According to research performed at MD Anderson Cancer Center (MDACC), monotherapy with Prolanta shows strong activity in a xenograft mouse model of human OC, substantially reducing both tumor volume and the number of tumors in a dose-dependent manner with no apparent toxicity noted. Prolanta preclinical data support the potential to be used in combination with chemotherapy or as a monotherapy for patients resistant to or those who cannot tolerate chemotherapy.

Novel Mechanism of Action: MDACC discovered that the primary mechanism of action of Prolanta is autophagocytosis or autophagy. Prolanta also has an anti-angiogenic effect. Furthermore, Prolanta competitively binds to prolactin receptors. When human prolactin binds to a receptor, it causes glutathione conjugation to chemotherapy, which transports the drug out of the cancerous cell.

Investment Opportunity: The FDA approved the IND in 2012. Oncolix expects to commence its first human trial in 2013. A Phase I, open label, dose escalation, 99-day study will evaluate safety, tolerability, efficacy trends and the optimal dose of Prolanta monotherapy in metastatic OC. Phase IIA trials are planned to further evaluate efficacy trends with Prolanta used alone or in combination with chemotherapy. Oncolix requires $3.5 million to complete the Phase I study and approximately $20 million to advance Prolanta through Phase IIb, which could be a pivotal trial for this orphan designation.

Science: Prolanta is an analog to human prolactin, identical except for a single amino acid substitution at the 129th position of this 199 amino acid protein. Somavert®, developed by the same scientist using a similar amino acid substitution in human growth hormone, is now sold by Pfizer for the treatment of acromegaly, or gigantism (2010 sales were $165 million for this orphan indication).

Patents: Oncolix holds in its name five issued US patents and additional foreign patents. Oncolix pays no milestones or royalties on these patents. In addition, the Healthcare Reform Bill provides 12 years of data exclusivity for biological products. Orphan status in Europe and Japan would provide ten years of market exclusivity.

Oncolix, Inc. www.oncolixbio.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



CONTACTPunit Dhillon Co-Founder, Directot, President and Chef Executive Officer

ADDRESS 4690 Executive Drive Suite 250 San Diego, CA, 92121 United States

TELEPHONE (855) OncoSec (662.6732)


COMPANY PROFILE

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumor cancers. ImmunoPulse addresses an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize the detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical’s core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine. OncoSec’s clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

MANAGEMENT

Punit Dhillon, Co-founder, Director, President and Chief Executive Officer

Mr. Dhillon was formerly Vice President of Finance and Operations at Inovio Pharmaceuticals, Inc., until March 2011. In his corporate finance role, Mr. Dhillon was pivotal to the company raising over $125 million through multiple financings and several licensing deals including early stage deals with Merck and Wyeth. He was also instrumental to the successful in-licensing of key intellectual property and a number of corporate transactions, including the acquisition and consolidation of Inovio AS, a Norwegian DNA delivery company, and led the merger with VGX Pharmaceuticals, which solidified Inovio’s position in the DNA vaccine industry. As head of operations, he successfully completed the integration of the VGX-Inovio merger including cost-cutting of over 30% through the synergy assessment of both companies, consolidation of four operating locations in to two bi-coastal offices, corporate rebranding and management of existing shareholders from both companies. Mr. Dhillon has been a consultant and board member for several early stage life science companies. Prior to joining Inovio, Mr. Dhillon worked for a corporate finance law firm as a law clerk. Previous to 2003, he worked with MDS Capital Corp. (now Lumira Capital Corp.) as an intern analyst.

Mr. Dhillon is a mentor to the TiE Young Entrepreneurs (TYE) Program where he recently led his team of students to win the 2012 global business plan competition in Atlanta. He is an active member in his community and advocate for cancer research and advancing the availability of healthcare.

In 2012, Mr. Dhillon helped raise over $30,000 to support the British Columbia Cancer Foundation and the British Columbia Children’s Hospital through charitable contributions. He is also the co-founder of Inbalance Network Inc., a wellness organization focused on promoting an active lifestyle and grassroots community involvement, including scholarships that support students pursuing post-secondary education. Mr. Dhillon has a Bachelor of Arts with honors in Political Science and a minor in Business Administration from Simon Fraser University. He resides in San Diego, California with his wife and two daughters, and enjoys being active through competitive running, swimming and biking.

OncoSec Medical, Inc. www.oncosec.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



t back :: next u

CONTACTEsteban Pombo-Villar COO

ADDRESS Head Office: Oxford BioTherapeutics Ltd 94a Milton Park Abingdon Oxon OX14 4RY

USA Oxford BioTherapeutics Inc San Jose Biocenter 5941 Optical CourtSan Jose, CA 95138 USA

Switzerland Oxford BioTherapeutics AG Aeschenvorstadt 71 4051 Basel Switzerland

TELEPHONE UK +44 (0) 1235 861770USA +1-408-960-7461Switzerland +41 (0) 61 225 42 90

FAX UK +44 (0) 1235 861771 Switzerland +41 (0) 61 225 42 91


YEAR FOUNDED2004

COMPANY PROFILE

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.

OBT’s strategy is to use its unique and integrated OGAP® discovery platform in alliances with the world’s leading antibody companies to develop OBT targets into novel antibody therapeutics and diagnostics. This approach is expected to deliver innovative and cost-effective medicines to fulfill unmet patient needs in the field of cancer. In parallel, OBT provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies.

Formed in 2004, OBT is privately held and is based near Oxford, UK.

MANAGEMENT

Christian Rohlff, PhD, CEO and FounderEsteban Pombo-Villar, PhD, Chief Operations OfficerJim Cornett, PhD, Chief Operations Officer (US) Jon Terrett, PhD, Chief Scientific OfficerTom Boone, Senior Vice President, Protein Sciences

Oxford BioTherapeutics www.oxbt.co.uk



WELCOM

ESPEAKERS

Sachs Associates



CONTACTSDr Tamar Raz VP Strategy and Marketing

ADDRESS Tel Aviv University campus, Ramat Aviv, Tel Aviv, Israel

TELEPHONE +972-3-6496580

FAX +972-3-6406675


YEAR FOUNDED1956

COMPANY PROFILE

Ramot is Tel Aviv University’s (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at the university to industry’s attention. The company provides the legal and commercial frameworks for inventions made by TAU faculty, students and researchers, protecting discoveries with patents and working jointly with industry to bring scientific innovations to the market.

Ramot enjoys a reputation as industry’s go-to source for inventions with product-potential, whether disruptive in nature, or complementary / supplementary to existing technologies. Its status as a trusted proponent of both university and business entities plays a vital role when engaging with industry to license TAU technologies to both long-established corporations and game-changing start-ups.

Founded in 1956 and one of Israel’s foremost research and teaching universities at the forefront of basic and applied research in many scientific disciplines, Tel Aviv University is located in Israel’s cultural, financial and industrial center.

In keeping with TAU’s goals, Ramot seeks to promote the university’s developments in applications that make a positive impact on society.

MANAGEMENT

Mr Shlomo Nimrodi, CEO

RAMOT at Tel Aviv University www.mucosis.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



CONTACTRichard M. Scruggs President & CEO

ADDRESS 2429 Bissonnet #393 Houston, TX 77005

TELEPHONE (713) 302-2998

FAX (832) 778-9103


YEAR FOUNDED2012

FINANCIAL SUMMARY

Privately-held.

COMPANY PROFILE

Rescue Therapeutics, Inc. (RTI) is developing RTI-79, a drug candidate that, when added to existing chemotherapy regimens, materially increases the efficacy of the chemotherapy. The Company’s initial focus is on second-line ovarian cancer patients scheduled to receive DOXIL. In multiple mouse xenograft studies using a drug-resistant lines of ovarian cancer, the RTI-79 treated tumors decreased in size over 45 days while DOXIL-only treated tumors nearly tripled in size. Initial safety data shows RTI-79 to be safe for long-term use. The Company recently held a pre-IND meeting with FDA. FDA has issued meeting minutes outlining a relatively short path to IND filing. Our goal is to have an active IND within 12 months. Over the long run, there are other opportunities for RTI to explore. In addition to ovarian/DOXIL, RTI has seen positive preclinical results in breast, pancreatic, prostate, colon and non-Hodgkins cell lines and with other chemotherapies such as velcade and cisplatinum.

MANAGEMENT

Richard M. Scruggs, President and CEOJames C. Sacchettini, PhD, Chief Science OfficerBruce F. Mackler, PhD, JD, VP, Regulatory and Clinical AffairsTheresa W. Fossum, DVM, MS, PhD, VP, Preclinical Affairs

Rescue Therapeutics, Inc. www.rti-bio.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



CONTACTSJeff Behrens President and CEO, Board of Directors

Julie Hermann Director, Business Development & Operations

ADDRESS 48 Wilde Road Newton, MA 02468

TELEPHONE (800) 513-1569

FAX (617) 752-3653


YEAR FOUNDED2006

FINANCIAL SUMMARY

Sialix has raised 2 rounds of angel financing, won numerous NIH grants, and recently signed an investment and option agreement with Momenta Pharmaceuticals.

COMPANY PROFILE

Sialix is developing a portfolio of therapeutic antibodies targeting glycan alterations in cancer. The emerging field of glycobiology offers a very attractive set of cancer-specific glycan targets found repeatedly on many solid tumors. Cancer-associated glycan alterations play important functional roles in tumor migration, cell adhesion, and metastasis; therefore, therapeutic antibodies have the potential to not only kill cancer cells but also disrupt critical biological functions in cancer progression. Sialix has signed an investment and option agreement with Momenta Pharmaceuticals on its first cancer program.

MANAGEMENT

Sialix is led by Jeff Behrens, MS/MBA, an experienced entrepreneur and biotech veteran who previously worked at Biogen Idec, Alnylam, and Edimer (funded by Third Rock Ventures). To complement its employees, Sialix has built relationships with leading contract research organizations and has a world-class team of scientific advisors from institutions including UCSD, MGH, Dana Farber, Harvard, Biogen, Smartcells, Alnylam, and Momenta.

Sialix, Inc. www.sialix.com

t back :: next u



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates



CONTACTSHenry Ji, Ph.D President and CEO

ADDRESS 6042 Cornerstone Ct West Suite B San Diego, CA 92121

TELEPHONE (858) 210 3701

FAX (858) 210 3759


YEAR FOUNDED2006

COMPANY PROFILE

Sorrento Therapeutics, Inc. (STI) is a development stage biopharmaceutical company engaged in the discovery, development and commercialization of novel, proprietary drug candidates for the treatment of patients suffering from a variety of conditions, including cancer, inflammation, metabolic and infectious diseases.

STI recently acquired a Phase 3-ready oncology drug candidate - Cynviloq (nanoparticle paclitaxel polymeric micelle) via merger with Igdrasol, Inc.

STI has developed and validated its novel proprietary technology platform for the construction of fully human antibody libraries. The resulting libraries possess great diversity based on deep sequencing studies as compared to publicly-available data from other commercially-utilized antibody libraries.

The G-MAB® libraries have been used establish preclinical programs in autoimmunity/inflammation, oncology, infectious disease, and metabolic disorders. STI’s focus is on the development of lead mAbs targeting G protein-coupled receptors (GPCRs) as well as immunomodulatory mAbs (PD-L1/PD1) for oncology and inflammation indications.

STI recently acquired worldwide rights to recombinant IntraVenous ImmunoGlobulins (rIVIG) and will apply its G-MAB® library technology to the development of rIVIG products.

Additional technology acquired from Igdrasol will allow for transformation of G-MAB® library into powerful antibody formulated drug conjugate (AfDC) platform.

STI is looking for strategic partnerships for Cynviloq as well as antibody and AfDC programs.

MANAGEMENT

Henry Ji, President and CEORichard Vincent, CFOJaisim Shah, CBO.

Sorrento Therapeutics, Inc. www.sorrentotherapeutics.com



WELCOM

ESPEAKERS

Sachs Associates



CONTACTWillem van Weperen Chief Executive Officer

ADDRESS J.H. Oortweg 19 2333 CH Leiden The Netherlands

TELEPHONE +31 71 3322251

FAX +31 84 8313409


YEAR FOUNDED2004

FINANCIAL SUMMARY

Seed 2004-2006: ±€1M

Series-A 2007: ±€4M

Series-B 2011: ±€6M

Interim round 2013: ±€2.5M

Accum. grants/credits: ±€5M

COMPANY PROFILE

to-BBB is a clinical stage blood-brain barrier company in the Netherlands with a proprietary technology (G-Technology®) to safely enhance brain drug delivery. Its lead product 2B3-101 is a brain-targeted formulation of Doxil/Caelyx, which has demonstrated higher brain levels but similar systemic exposure, resulting in therapeutic benefits in animal studies with 2B3-101. It is now achieving high therapeutic dose levels in a clinical phase I/IIa trial in patients with solid tumor brain metastases and glioma. Preliminary efficacy has been shown both intra- and extra-cranially. Upon determining maximum tolerated dose, the expansion phase of the trial will study preliminary efficacy in specific patient populations: 1) Breast Cancer brain metastases with or without trastuzumab (Herceptin). 2) Small Cell Lung Cancer brain metastases; 3) Melanoma brain metastases, and; 4) malignant glioma; The expansion phase will allow selection of most responsive tumor types for further development, while performing due diligence processes and negotiation discussions for licensing purposes.

to-BBB is developing several other products for brain diseases, either internally or in collaboration with pharma/biotech partners. Furthermore, it is evaluating oncology compounds that can benefit from the G-Technology by combining a slow release profile with enhanced brain delivery for metastatic disease including brain metastases or for primary brain tumors.

MANAGEMENT

Willem van Weperen, MSc, MBA, Chief Executive OfficerPieter Gaillard, PhD, Chief Scientific Officer/founderFredrik Lonnqvist, MD, PhD, Assoc. Prof., Chief Medical Officer

to-BBB technologies BV www.tobbb.com

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



TVAX Biomedical, Inc. www.tvaxbiomedical.com

COMPANY PROFILE

TVAX Biomedical is a clinical stage development company advancing its targeted cell-based immunotherapy for the treatment of cancer. The company’s novel therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated.

TVAX Immunotherapy is a unique personalized combination of cancer cell vaccination and “killer” T cell treatment. This treatment has demonstrated the potential to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy.

The key distinction between TVAX and other cancer immunotherapy companies is that TVAX Immunotherapy uses BOTH cancer vaccination AND activated “killer” T cell treatment – two separate approaches that have each demonstrated limited therapeutic potential, though neither has the efficacy to be a viable standalone treatment.

TVAX’s lead therapy, TVI-Brain-1, is currently being evaluated for the treatment of brain cancer. The company has been authorized by the United States Food and Drug Administration (FDA) to conduct a pivotal Phase 3 trial to support TVI-Brain-1’s potential FDA approval.

MANAGEMENT

Phil Haworth, Ph.D., J.D., Chief Executive OfficerGary Wood, Ph.D., Chief Science OfficerTammie Wahaus, CPA, Chief Financial Officer

CONTACTSPhil Haworth, Ph.D., J.D. CEO

Stephanie Diaz Investor Relations

Tammie Wahaus CFO

ADDRESS TVAX Biomedical 8006 Reeder Street Lenexa, KS 66214

TELEPHONE (913) 492-2221

FAX (913) 492-2243

EMAIL [email protected]@vidasp.com

YEAR FOUNDED2004

t back :: next u



WELCOM

ESPEAKERS

Sachs Associates



Sponsors, Supporters, Regional Partners

t back :: next u

http://dslrf.org/actwithlove/

The Dr. Susan Love Research Foundation works to eradicate breast cancer and improve the quality of women’s health through innovative research, education, and advocacy. Learn about our programs. Find out how you can support the Foundation and the groundbreaking research that will end breast cancer in our lifetime.

We will meet this challenge by being fast, flexible, and project-based. We will identify needs and determine how these needs can be quickly met, not by emulating existing nonprofit organizations but by designing a new model specific to the tasks at hand. We will find the most effective route to breast cancer eradication, whether it is in the not-for-profit arena, the for-profit arena, or both. We will approach problems by collaborating and coordinating with other organizations. We will facilitate solutions to be adopted by others.

The goal of the Dr. Susan Love Research Foundation is to identify the barriers to research and to then create new solutions.

What Makes Us Different

More than $4 billion dollars has been spent on breast cancer research in the United States. Yet we still do not know what causes breast cancer or how to prevent it. At the Dr. Susan Love Research Foundation, we believe that to eradicate breast cancer we need to begin where breast cancer begins—in the breast ducts. The Foundation is engaging in an extraordinary opportunity to focus research on the breast ducts and understand how the breast works. With your support, we will determine how to prevent and eradicate breast cancer once and for all.

Dr. Susan Love Research Foundation 2811 Wilshire Blvd., Suite 500 Santa Monica, California 90403

Tel: 310-828-0060 (local) or 1-866-569-0388

Dr Susan Love Research Foundation



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates




FreeMind www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.

Tel: (617) 648-0340 Fax: (617) 904-1767 Email: [email protected]

BostonFreeMind Group423 Brookline Ave. #124Boston, MA 02215

Washington DCFreeMind Consultants4094 Majestic lane # 269Fairfax, VA 22033

JerusalemFreeMind GroupHi - Tech CenterHebrew UniversityJerusalem 95702Israel



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates




http://prostatecanceralliance.org/

Our Mission:To diminish the global burden of prostate cancer by enhancing local, national, and international advocacy, and awareness building capacities and access to affordable and appropriate care.

Our Goals:No man on our planet should be denied access to prostate cancer information, diagnosis or treatment.

The Global Prostate Cancer Alliance is an inclusive collaboration of all prostate cancer stakeholders from around the world. No one is charged a fee to join and everyone is encouraged to participate, collaborate and share knowledge and technical assistance.

We are an international leader in facilitating local and national prostate cancer advocacy and awareness dialogue and media connections.

We promote understanding of local issues through dissemination of leading edge news and development of media, online education, archives, and publications.

We foster efficient and effective local, national and international strategic planning through information sharing and partnering between members and other stakeholder organizations.

We develop and sustain a system for global delivery of advocacy resources and information to the array of stakeholders who must work together to ensure that the rights and interests of trial participants, eventual users, and communities are fully represented and respected in the scientific and product development processes.

Darryl Mitteldorf, LCSW

Organizing Secretary

Global Prostate Cancer Alliance

Email: [email protected]

Tel: 01 212 673 4920

Global Prostate Cancer Alliance



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates




http://www.thebiotechclub.org/

The GSAS Harvard Biotechnology Club is a non-profit, student organization that hosts events and provides services that allow members to explore the world of business and biotechnology. The Biotech Club’s mission is to bridge the gap between industry and academia by building relationships with companies operating in the biotechnology and healthcare sphere.

GSAS Harvard Biotechnology Club



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates




LaVoie Group www.lavoiegroup.com

LaVoie Group (LG) helps its clients achieve their business goals by providing integrated reputation management and communications programs that build enterprise differentiation and engage target stakeholders to create value. The breadth and depth of our experience uniquely positions LG to help clients with stakeholder engagement through carefully executed strategy and programming. What We Do:

• Provide depth and breadth in the design and execution of communications programs that take a company and its products from development through launch and commercialization

• Bring a proven track record designing and executing programs that effectively position and engage our clients’ key stakeholders, with measureable ROI

• Help our clients gain recognition and optimal value for their technologies, products and businesses

• Create and execute programs with a targeted market focus and global point of view

• Work globally through IPREX network of independent agencies

201 BroadwayCambridge, MA 02139

Email: [email protected] Tel: 617 374 8800



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates




http://lifesciencenation.com/

Life Science Nation (LSN) is the premier sourcing platform for market intelligence and prospect pipeline development in the life science arena. LSN enables life science professionals to generate a list of qualified global targets that are a fit for their company’s products, services, and fundraising efforts. The ability to generate these Global Target Lists (GTLs) makes life science professionals more effective and efficient.

Finding the right people, products, and services in the life science arena is a conundrum - one that is made more difficult by the lack of resources to help professionals take advantage of the larger global market rather than focus regionally.

The LSN platform addresses this issue by providing sales, marketing, business development, and fundraising professionals unprecedented access to the new and existing life-science companies around the globe.

As a leading B2B source for decision-maker contacts in the life science industry, the LSN platform has more than 24,000 life-science organizations worldwide, including biotechnology, pharmaceutical, medical technology, service providers, suppliers, nonprofits, and investors.

LSN employs a unique grass-roots data-gathering process and a two-tier data-validation procedure to collect current and accurate information on these life science organizations, including their company profile, management team, product pipeline, licensing opportunities, financing rounds, and deals. Current investment mandates are included for investor organizations.

LSN offers the industry’s most complete data set of life science investors - from profiles of the hottest new segment (the family office) to a historical view of every private equity and venture capital investor that has participated in a life science deal in the past decade.

This extensive research and data-mining effort forms the underpinnings of the LSN platform - a powerful productivity tool that provides deep insight into target markets, top-tier accounts, and global business opportunities and helps clients earn a measurable ROI on their marketing investment.

9B Hamilton Place, Boston, MA, 02108, USA

Tel: +1 (617) 600-0668Email: [email protected]

Life Science Nation



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates




http://www.lls.org

The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.

LLS is the world’s largest voluntary health agency dedicated to blood cancer. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Our Key Priorities will ensure that: The Leukemia & Lymphoma Society helps blood cancer patients live better, longer lives.

Research SuccessesAt The Leukemia & Lymphoma Society (LLS) we’re committed to funding research to help cure patients with leukemia, lymphoma, myeloma and related malignancies and improve their quality of life.

When LLS was founded in 1949, a blood cancer diagnosis was almost always fatal. Thanks in part to innovative research funded by LLS, survival rates have doubled, tripled and even quadrupled for blood cancer patients.

The Leukemia & Lymphoma Society National Office1311 Mamaroneck Avenue, Suite 310White Plains, NY 10605

Tel: (914) 949-5213

Leukemia & Lymphoma Society



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates




www.massbio.org

The Massachusetts Biotechnology Council (MassBio), a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation’s oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide.

We provide services and support to foster the biotechnology industry in Massachusetts and sustain our position as a world leader.

There are more than 600 members in MassBio representing all facets of the industry. Our membership includes biotechnology companies, businesses related to the industry, major teaching hospitals and world-leading academic institutions.

300 Technology Square, 8th FloorCambridge, MA 02139

Tel: 617.674.5100

MassBio



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates




www.curemelanoma.org

Melanoma is the deadliest form of skin cancer, and it is one of the cancers whose incidence is increasing fastest in this country. In 2007, melanoma touched the lives of Debra and Leon Black when Debra was diagnosed with the disease. With melanoma incidence rising dramatically and survival for those with advanced disease remaining static at less than 15 percent, the Blacks formed the Melanoma Research Alliance (MRA) under the auspices of the Milken Institute. Thanks to their generous ongoing support, all public donations to MRA go directly to melanoma research. Our ultimate goal is to find a cure by funding the most promising melanoma research worldwide that will accelerate progress and improve outcomes for patients and all who are at risk.

MRA is the largest private funder of melanoma research. To date, MRA has awarded nearly $48 million to 116 research programs to make transforming advances in the prevention, diagnosis and staging, and treatment of melanoma, including research in biological causes of carcinogenesis, skin screening, biomarkers, imaging, immunotherapy, molecularly targeted therapy, and combination therapy.

Collaboration is at MRA’s core—from the team approaches to research that we fund, to the way we find partners who can help us realize our vision. Our allies are also focused on increasing public knowledge about the seriousness of melanoma and ways to reduce risk and improve early detection. MRA is pleased to have the generous support of a growing list of corporate allies in the fight against melanoma to amplify our message and garner the resources necessary to advance our mission. Through a unique partnership with Bruce Springsteen and the Danny Fund, MRA has been engaged in a series of public awareness initiatives urging people to protect themselves from the sun’s damaging rays, avoid indoor tanning, and be aware of changes in their skin. Together with our allies and your support, we are working toward the day when no one will suffer or die from melanoma..

Melanoma Research Alliance1101 New York Avenue, NW, Suite 620, Washington, DC 20005

Email: [email protected]: 202-336-8935

Melanoma Research Alliance



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates




Swiss Biotech Association www.swissbiotech.org

SwissBiotech – One Nation – One Biotech Cluster

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.

Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Further inquiries:SwissBiotech, Executive OfficeTel. +41 (0)44 455 56 78 [email protected]



WELCOM

ESPEAKERS

t back :: next u

Sachs Associates




www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies.

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc.35 W. 35th Street, 5th Floor, New York, NY 10001-2205

Tel: 212.827.0020 Fax: 212.827.0028 Fax

Tiberend Strategic Advisors, Inc.



WELCOM

ESPEAKERS

Sachs Associates




t back :: next u

Torreya Partners LLC www.torreyapartners.com

Torreya Partners LLC is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide.

Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco.

UK12 St James’s SquareLondon SW1Y 4LB+44 0207 104 2310

New York117 East 55th Street New York, NY 10022 (212) 331-7843

www.sachsforum.com

Sachs Associates is a London based international conference organiser which produces high profile events for the bio-pharmaceutical and financial community. These events are held In Europe and the USA; currently in Boston and Zurich.

The company was established in 1992 and ran emerging growth and emerging market investor forums in association with Dow Jones and then Bloomberg LP over a ten year period.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Multimedia ExposureSachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies,including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long establishedrelationships with other financial press organisations globally, which allow further effective distribution onbehalf of its clients.

Eminent SpeakersSachs Associates is committed to ensuring that its events continue to provide forums with the participation ofthe most eminent speakers from the public and private sectors. Through its reputation and its long-establishedlocal relationships, the Company has attracted the very senior political and economic personalities as speakersat its events.

Sponsorship and Marketing Opportunities for forthcoming eventsSachs Associates has developed an extensive knowledge of the key individuals operating within the Europeanand global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at theforefront of the industry and provides a powerful tool by which to increase the position of your company in thismarket.

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients.All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most outof attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:• Conference Sponsor – including workshops and social events• Exhibition stands• Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please callZoe Harris on +44 203 463 4890.

Sachs Associates



WELCOM

ESPEAKERS

Sachs Associates



Organisers

www.sachsforum.comSachs Associates



WELCOM

ESPEAKERS

www.sachsforum.comSA

CH

S

CA

NC

ER

B

IO

P

AR

TN

ER

IN

G

FO

RU

M

27 Belsize LaneLondon

NW3 5AS

Tel: +44 (0)203 463 4890Fax: +44 (0)207 691 7919

Follow us on Twitter – @SachsAssociates

We look forward to seeing you at:

13th Annual Biotech in Europe Investor Forum

30 September - 01 October 2013 • Hilton Zurich Airport Hotel

http://www.sachsforum.com/zurich13

speakers annual sachs cancer bio partnering forum€¦ · speakers annual sachs cancer bio...

Documents